Abstract: Mitochondria are the sites of oxidative metabolism in eukaryotes where the metabolites of sugars, fats, and amino acids are oxidized to harvest energy. Notably, mitochondria store Ca\(^{2+}\) and work in synergy with organelles such as the endoplasmic reticulum and extracellular matrix to control the dynamic balance of Ca\(^{2+}\) concentration in cells. Mitochondria are the vital organelles in heart tissue. Mitochondrial Ca\(^{2+}\) homeostasis is particularly important for maintaining the physiological and pathological mechanisms of the heart. Mitochondrial Ca\(^{2+}\) homeostasis plays a key role in the regulation of cardiac energy metabolism, mechanisms of death, oxygen free radical production, and autophagy. The imbalance of mitochondrial Ca\(^{2+}\) balance is closely associated with cardiac remodeling. The mitochondrial Ca\(^{2+}\) uniporter (mtCU) protein complex is responsible for the uptake and release of mitochondrial Ca\(^{2+}\) and regulation of Ca\(^{2+}\) homeostasis in mitochondria and consequently, in cells. This review summarizes the mechanisms of mitochondrial Ca\(^{2+}\) homeostasis in physiological and pathological cardiac remodeling and the regulatory effects of the mitochondrial calcium regulatory complex on cardiac energy metabolism, cell death, and autophagy, and also provides the theoretical basis for mitochondrial Ca\(^{2+}\) as a novel target for the treatment of cardiovascular diseases.

Keywords: mitochondria; Ca\(^{2+}\) homeostasis; cardiac remodeling; mitochondrial Ca\(^{2+}\) uniporter protein complex; cardiovascular diseases

1. Introduction

Mitochondria are called “power stations” because it is here that cells perform aerobic respiration and produce energy. In addition to generating energy for cells, mitochondria also participate in apoptosis, the tricarboxylic acid cycle, Ca\(^{2+}\) signal transduction, information transmission, and other processes, and also regulate cell growth and cell cycle [1].

The heart is the largest energy-consumption organ and mitochondria are its main source of energy [2]. Unlike non-cardiac mitochondria, adult cardiac mitochondria are partially immobile and their ability to move and distribute in the cytoplasmic tubular network is limited [3]. According to the location and function of mitochondria in adult cardiomyocytes, they can be divided into the following three categories: interfibrillar mitochondria (IFM), subsarcolemmal mitochondria (SSM), and perinuclear mitochondria [4]. IFM and SSM are distinct physiological types located at different regions of cardiac tissue [4,5]. IFM is mainly of a tubular structure, which is aligned longitudinally between myofibrils. Earlier studies have shown that IFM has a higher substrate oxidation rate (about 1.5 times) than SSM. Therefore, IFM located in myofibrils is thought to provide a large amount of energy for myocardial cell contraction [6]. Their tubular cristae are involved in ATP production for cardiac contractions and Ca\(^{2+}\) signaling [6]. SSM with a lamelliform structure is positioned mainly beneath the subsarcolemmal [7]. Under normal conditions, mitochondria produce ATP through oxidative phosphorylation, which provides energy for the normal contraction and metabolism of cardiomyocytes, and maintains cellular homeostasis [2]. The pathophysiology of cardiomyocytes is associated with changes in mitochondria, including swelling.
loss or reorientation of cristae, structural deformation, or internal and external ventricular vacuoles [8]. So the stability of mitochondrial morphology and function is particularly important for the maintenance of normal cardiac physiological function [7].

Mitochondrial homeostasis refers to the mechanism that maintains the integrity of the mitochondrial genome and proteome and the normal function of mitochondria [9]. Mitochondrial Ca\textsuperscript{2+} homeostasis is an important aspect of mitochondrial homeostasis. Mitochondrial Ca\textsuperscript{2+} homeostasis plays a series of key roles in cell physiological and pathological processes, including energy metabolism, apoptosis, and the production of reactive oxygen species (ROS) [10]. Mitochondrial Ca\textsuperscript{2+} exchange, that is, Ca\textsuperscript{2+} flowing in and out of mitochondria, is the most fundamental factor for balancing cell death and energy demand. The imbalance of mitochondrial Ca\textsuperscript{2+} homeostasis plays a key role in the occurrence and development of cardiovascular diseases [11,12]. Mitochondrial Ca\textsuperscript{2+} channels are a promising therapeutic target for alleviating irreversible and severe symptoms of cardiac dysfunction [13]. Targeting mitochondrial Ca\textsuperscript{2+} homeostasis provides new therapeutic strategies for aging-related diseases, particularly cardiovascular diseases [14].

Under physiological and pathophysiological conditions, intracellular Ca\textsuperscript{2+} plays an important role in regulating excitation–contraction (EC) coupling, cell proliferation and differentiation, and the cell death of cardiomyocytes. Cytoplasmic Ca\textsuperscript{2+} ([Ca\textsuperscript{2+}]\textsubscript{cyto}) affects a variety of other targets, including ion channels and transporters, signaling cascades, gene transcription, and mitochondrial ATP production [15,16]. However, Ca\textsuperscript{2+} is not only a key element in EC-coupling, but also a key second messenger in cardiac signal transduction, controlling excitatory, metabolic, and transcriptional processes [17]. Intracellular Ca\textsuperscript{2+} fluctuations that activate contractile apparatus promote the excitation–contractile coupling of cardiomyocytes. During electrical stimulation, the amount of Ca\textsuperscript{2+} released from the sarcoplasmic reticulum (SR) into the cytoplasm regulates the formation of cross-bridges between myofilaments, thus determining the force generated by the myocardium. The diastolic phase promotes the dissociation of Ca\textsuperscript{2+} from troponin C, and cytosolic Ca\textsuperscript{2+} clearance determines the pattern of muscle relaxation. Therefore, defects in intracellular Ca\textsuperscript{2+} processing may be the cause of impaired systolic and diastolic function in hearts.

In adult myocardium, the sarcoplasmic reticulum (SR) is the main source and reservoir of cytoplasmic Ca\textsuperscript{2+}. SR regulates Ca\textsuperscript{2+} release through Ca\textsuperscript{2+} release channels or type 2 Ryanodine receptor (RyR2), and is essential for the excitation–contraction (EC) coupling of cardiomyocytes through the induced Ca\textsuperscript{2+} release (CICR) mechanism [18,19]. The interruption of Ca\textsuperscript{2+} treatment can lead to the pathogenesis of many diseases, such as Alzheimer’s disease, Huntington’s disease, and congestive heart failure [20]. Mitochondrial Ca\textsuperscript{2+} regulates different processes that are crucial to cellular function, such as energy production (ATP), mitochondrial permeability transition pore (mPTP) opening, triggering, and preventing apoptosis [21]. There are several potential Ca\textsuperscript{2+} influx and outflow sites in mitochondria. The concentration of Ca\textsuperscript{2+} in mitochondria depends on the pathways across the endoplasmic reticulum, mitochondria-associated membranes (MAMs), and mitochondria [22]. It has long been recognized that Ca\textsuperscript{2+} signaling in mitochondria not only regulates mitochondrial metabolism but also promotes cell death. However, under cardiac ischemia-reperfusion injury and other pathological conditions, cytoplasmic Ca\textsuperscript{2+} overload prevents mitochondrial Ca\textsuperscript{2+} from upregulating mitochondrial ATP production and promotes the mitochondrial death pathway [23,24]. In addition, mitochondrial Ca\textsuperscript{2+} activates TCA cycle dehydrogenase and regulates nicotinamide adenine dinucleotide (NADH) production, affecting the antioxidant capacity of cells and the production of mitochondrial ROS, thereby playing an important role in regulating the redox state of cells [25]. Therefore, the mitochondrial Ca\textsuperscript{2+} pathway plays an important role in the regulation of cellular functions and the cell death pathway. We believe that mitochondrial Ca\textsuperscript{2+} homeostasis is a double-edged sword regulating cardiac mitochondrial function. Although mitochondria Ca\textsuperscript{2+} overload prevention has attractive therapeutic potential, a wide range of diseases, and no entity for mitochondrial Ca\textsuperscript{2+} exchange into clinical trials [26]. This review provides an overview of mitochondrial Ca\textsuperscript{2+} homeostasis in regulating cardiac
energy metabolism, cell death, ROS production and autophagy. As well as the mechanism of mitochondrial Ca²⁺ homeostasis regulation in physiological and pathological heart remodeling, it provides a theoretical basis for mitochondrial Ca²⁺ as a new therapeutic target for cardiovascular diseases and clinical treatment.

2. Mitochondrial Ca²⁺ Homeostasis and Cardiac Energy Regulation

In the heart muscle tissue, the action potential (AP) activates voltage-gated Na⁺ channels and induces the rapid depolarization of the cell membrane, facilitating the voltage-dependent opening of L-type Ca²⁺ channels and Ca²⁺ entry into the cells. With a Ca²⁺ influx, the sarcoplasmic reticulum (SR) Ryanodine Type 2 (RyR2) channel is activated, resulting in a large amount of Ca²⁺ release from SR, leading to a transient increase in cytosolic Ca²⁺ and the activation of myofilament cross-bridge formation. At the end of contraction, Ca²⁺ enters the SR through SR Ca²⁺-ATPase (SERCA) and flows out of the extracellular space through the Na⁺/Ca²⁺ exchanger (NCX) [27,28].

Furthermore, SERCA1, 2, and 3 are variable splicing isoforms of the SR Ca²⁺-ATPase gene. In cardiac tissue, the Ca²⁺-ATPase (SERCA2a) isoforms promote Ca²⁺ storage and distribution in SR. The SERCA2a of the sarcoplasmic reticulum (SR) maintains a 1000-fold Ca²⁺ gradient on the cardiac sarcoplasmic reticulum and plays a dominant role in the excitation–contraction coupling and contractility of the heart. During systole, action potentials induce a small amount of Ca²⁺ to flow through L-type Ca²⁺ channels from the sarcolemma. This influx initiates Ca²⁺ releasing channels or Ryanodine receptors ( RyR) to release Ca²⁺ in large quantities from SR Ca²⁺ stores [29]. During diastole, Ca²⁺ entering the SR or extracellular lumen is quickly removed. This process is promoted mainly by SERCA (70–80% Ca²⁺ removal in higher mammalian and human myocardium) and a small amount by sarcolemmal Na⁺, Ca²⁺-exchange (20–30%) and a slower Ca²⁺-transport system [30]. The Ca²⁺ in SR binds mainly to the SR Ca²⁺ binding proteins calsequestrin and calreticulin and histidine-rich binding proteins [31]. As is known, Ca²⁺ is stored in the vicinity of Ca²⁺ release channels via the proteins triadin and Junctin [32,33], which is likely due to the accelerated availability of Ca²⁺ near ryanodine receptors during early contraction. In addition to SERCA2a, the phosphorylation status of the ryanodine receptor and its accessory proteins may modulate Ca²⁺ release at the SR level [34].

Mitochondria occupy more than 30% of the heart cellular volume and occur close to the main energy-consuming sites, that is, the myofilaments, SR, and t-tubules. Mitochondria are the heart’s energy factories, providing more than 90% of ATP for cardiac contraction [35,36]. Mitochondria produce energy through oxidative phosphorylation, which is consumed by cardiac excitation–contraction (EC) coupling. Mitochondria play an important role in cardiac physiology and pathophysiology, and Ca²⁺ is at the core of cardiac EC coupling [28]. In chronic heart failure, EC disorder may adversely affect mitochondrial Ca²⁺ uptake and energy production, resulting in a vicious circle of cardiac systolic dysfunction and energy loss [37]. It has been shown in cell models that mitochondria regulate the TCA cycle and increase the activity of the electron transfer chain (ETC) to promote ATP production through Ca²⁺ uptake [38]. Mitochondrial oxidative phosphorylation synthesizes ATP through a Ca²⁺-dependent process, so the maintenance of mitochondrial Ca²⁺ homeostasis is crucial for the regulation of mitochondrial ATP production [39]. Under the electrochemical gradient produced by strong Ca²⁺ influx, mitochondria primarily uptake Ca²⁺ through the mitochondrial Ca²⁺ monomolecular carrier (MCU) [40,41]. Mitochondrial Ca²⁺ activates three key enzymes in the TCA cycle, of which, isocitric dehydrogenase and α-ketoglutarate dehydrogenase are activated in a Ca²⁺-dependent manner [38,42–46]. Territo and Balaban found that Ca²⁺ also activated the F1/F0 ATPase [47,48], and increased respiration in less than 100 ms, a rate sufficient to support the conversion of cardiac function in vivo. This triggers an increase in the conversion of nicotinamide adenine dinucleotide (NAD⁺) to reduced NADH, moving electrons along the ETC from complex I to complex IV. Protons (H⁺) are pumped into the intermembrane space by complexes I, III, and IV, establishing a proton motive force via electrochemical potential and a proton gradient.
Compound V is driven by this proton motive force to convert ADP into ATP [47–49]. ATP is then released into the cytoplasm by adenine nucleoside transporter (ANT) on the inner membrane of mitochondria and voltage-dependent anion channel (VDAC) on the outer membrane of mitochondria [50–52] (Figure 1). High phosphate buffer systems, such as creatine kinase (CK) isoenzymes and highly diffused phosphocreatine (PCr), exist in the cytoplasm and limit a large number of ATP changes while ADP shuttles from ANT and effectively transfers energy signals from the ATP hydrolysis site to mitochondria. In addition, in complexes I and III, some electrons leak out of the ETC and react with oxygen to form superoxides. In other words, mitochondrial ROS production is also a Ca$^{2+}$ dependent process [53–55]. In conclusion, mitochondrial Ca$^{2+}$ homeostasis plays an important role in regulating ATP production and ROS generation [39]. Mitochondria are the main sources of ATP and ROS, and their functioning is strictly controlled by mitochondrial Ca$^{2+}$. In the physiological process of workload, the uptake of mitochondrial Ca$^{2+}$ needs to match the balance of energy supply and demand while maintaining the antioxidant capacity in a reduced state to prevent excessive ROS [56].

Figure 1. Under physiological conditions, Ca$^{2+}$ regulates excitation–contraction coupling, mitochondrial energetics, and ROS production in cardiomyocytes. In cardiomyocytes, action potential causes Ca$^{2+}$ to enter cells from L-type Ca$^{2+}$ channels (Ica, L), and the influx of Ca$^{2+}$ activates Ryanodine Type 2 (RyR2) on the sarcoplasmic reticulum (SR), resulting in a large release of Ca$^{2+}$ from the SR and subsequent binding to troponin C promoting myofilament cross-bridge formation, which causes cardiac contraction. During systole, Ca$^{2+}$ enters SR via SR Ca$^{2+}$-ATPase (SERCA) and exits the extracellular space via the Na$^{+}$/Ca$^{2+}$ exchanger (NCX). Mitochondria take up Ca$^{2+}$ through MCU, and Ca$^{2+}$ activate two key enzymes, isocitrate dehydrogenase, and α-ketoglutarate dehydrogenase, of the TCA cycle and regenerate NADH$^+$ from NAD. This causes electrons to move along the electron transfer chain (ETC) from complex I to complex IV. Complexes I, III, and IV pump protons (H$^+$) into the intermembrane space, forming proton-motive forces bearing electrochemical potential and a proton gradient. Compound V converts ADP to ATP under proton drive. ATP is released into the cytoplasm through the adenine nucleoside transporters (ANT) on the inner membrane of mitochondria.
In addition to ATP production by the activation of TCA cyclase and ATP synthase, mitochondrial Ca\(^{2+}\) has been reported to directly activate L-type Ca\(^{2+}\) channels in adult guinea pigs and mouse vascular myocytes, increasing NADH production, oxygen consumption, and ROS production \[57–59\]. Therefore, a change in L-type Ca\(^{2+}\) activity may play an important role in Ca\(^{2+}\)-dependent mitochondrial energetics, but the precise mechanism underlying his phenomenon remains to be elucidated. It has also been reported that the activation of L-type Ca\(^{2+}\) channels not only regulates Ca\(^{2+}\) influx but also \(\Psi_m\) independently of mitochondrial Ca\(^{2+}\) uptake \[59\]. Mitochondrial Ca\(^{2+}\) plays a dual role in the process of energy supply and demand matching of cardiomyocytes. L-shaped Ca\(^{2+}\) channels can lead to a Ca\(^{2+}\) influx, triggering the release of large amounts of Ca\(^{2+}\) from the SR during cardiac systolic and diastolic coupling. Furthermore, Ca\(^{2+}\) binds to troponin C and thereby induces cardiac contraction. During the diastolic phase, Ca\(^{2+}\) is transported from SERCA to SR, or through the NCX to the extracellular membrane \[60\]. \(\beta\)-adrenergic stimulation increases the rate and amplitude of cytosolic Ca\(^{2+}\) transient. ATP is hydrolyzed to ADP, which then enters mitochondria through the ANT to activate the F1F0-ATPase and regenerate ATP. This accelerates electron flow in the ETC, and NADH is oxidized to NAD+. This is called the “pull” condition. At the same time, MCU uptakes Ca\(^{2+}\) into the mitochondria, activates key enzymes of the TCA cycle, and converts NAD+ into NADH. This is called the “push” condition (Figure 1). Therefore, mitochondrial Ca\(^{2+}\) can not only pull electrons along the ETC to increase energy consumption but also push electrons from the TCA cycle into the ETC to regenerate energy; this is known as “parallel activation” \[47,61,62\].

3. Mitochondrial Ca\(^{2+}\) Homeostasis and the Regulation of Cardiac Cell Death

As mentioned above, mitochondrial Ca\(^{2+}\) not only regulates mitochondrial energy but also promotes cell necrosis in case of Ca\(^{2+}\) overload. A common cause of necrosis is an impaired mitochondrial energy metabolism, resulting in a sharp decline in ATP levels. Necrosis plays an important role in many pathological conditions, including ischemia/reperfusion injury, trauma, and neurodegenerative diseases. Thus, the maintenance of mitochondrial Ca\(^{2+}\) homeostasis is of critical importance. Studies have shown that the inhibition of mitochondrial Ca\(^{2+}\) uptake can significantly reduce cell death \[63\].

The history of Ca\(^{2+}\)-induced cell death can be traced back to Fleckenstein’s study in 1974. He found that excessive Ca\(^{2+}\) entry into cells may be the cause of death after cardiac ischemia \[64\]. Under physiological conditions, the inner membrane of mitochondria is impermeable, but under certain conditions, Ca\(^{2+}\) accumulation and oxidative stress in mitochondria can trigger the opening of highly conductive pores in the mitochondrial intermembrane. This phenomenon, known as mitochondrial permeability transition (MPT), leads to changes in mitochondrial morphology and function. MPT is a Ca\(^{2+}\)-dependent process and is regulated by factors, such as inorganic phosphorus, ATP deficiency, low pH, and oxidative stress (e.g., ROS, oxidized GSH, and pyridine nucleotide pools) \[65–67\]. MPT is followed by mitochondrial osmotic swelling, membrane rupture, and the release of cytochrome c and other mitochondrial proteins into the cytoplasm. During electron transfer, an electrochemical gradient is established that promotes ATP synthase to produce ATP. However, under pathological conditions, mitochondrial Ca\(^{2+}\) overload causes the opening of the mPTP, allowing molecules of less than 1.5 kDa to pass freely \[23,24\]. This results in the disruption of the mitochondrial membrane potential, alteration of membrane permeability, reduction in ATP synthesis, mitochondrial rupture, loss of matrix solute (including GSH, pyridine nucleotides, and ADP/ATP), and the release of cytochrome C from the intermembrane space \[24\] (Figure 2). Several studies reinforce that an mPTP opening caused by mitochondrial Ca\(^{2+}\) overload is a key cause of cardiomyocyte death in ischemia-reperfusion injury \[24\]. Moreover, the opening of mPTP and the subsequent uncoupling of mitochondria leads to the active hydrolysis of cytosolic ATP and a decrease in ATP content in the cytoplasm, resulting in the disturbance of intracellular Ca\(^{2+}\) homeostasis, the activation of various catabolic enzymes (protease, phospholipase, etc.), and cell death. The use of drugs to inhibit or knockout mPTP components holds great promise for
preventing cardiomyocyte death. Although the mPTP opening is primarily associated with the necrosis of cells, several cytotoxic drugs have been shown to mediate apoptosis through Ca\(^{2+}\)-mediated MPT. A persistent PTP opening can be detrimental to mitochondrial function, but a transient opening or flickering of PTP is observed in many cell types and isolated mitochondria \cite{70}. The frequency of transient PTP opening was primarily determined by free matrix Ca\(^{2+}\) \cite{71,72}. Physiological PTP flicker is considered to be the mechanism of Ca\(^{2+}\) release from overloaded mitochondria \cite{70,73–75}. In this way, PTP flicker can be used as a physiological safety valve to prevent Ca\(^{2+}\) overload, mitochondrial failure, and thereby, cell death (Figure 2). Studies have shown that the inhibition of PTP opening by cyclosporine A (CsA) inhibited mitochondrial Ca\(^{2+}\) release from mitochondria in rat cardiocytes \cite{76}.

![Figure 2. Dual role of mPTP in cardiac physiology and pathology.](image)

Importantly, Ca\(^{2+}\) not only plays a key role in the regulation of cell death, but is also a critical sensitizing signal in mitochondrial pro-apoptotic transition \cite{77}. Mitochondria are important checkpoints in the process of apoptosis, and they activate the internal pathways of apoptosis by releasing cytochrome C and other mitochondrial proteins into the cytosol. Mitochondrial Ca\(^{2+}\) overload is also one of the pro-apoptotic pathways, as it is known for inducing mitochondrial swelling, rupturing the outer membrane, and then releasing mitochondrial apoptosis factors into the cytosol \cite{78}. Therefore, studies have investigated...
whether mitochondrial Ca\(^{2+}\) is involved in the release of pro-apoptotic proteins. The ceramide treatment of HeLa cells promoted Ca\(^{2+}\) release from the endoplasmic reticulum and loading into mitochondria, resulting in swelling and fragmentation of organelles and cytochrome C release. When bc1-2 is overexpressed and endoplasmic reticulum calcium levels are reduced, cytochrome C release is prevented \[79\]. Additionally, Ip3-mediated physiological Ca\(^{2+}\) signals are converted by ceramide into apoptosis-inducing factors \[80\]. Type 3 IP3Rs (IP3R-3) is located at MAM and induces apoptosis by preferentially transmitting apoptotic Ca\(^{2+}\) signals to mitochondria. Apoptosis was blocked by silencing IP3R-3 expression, and Ip3R-3 downregulation significantly reduced agonist-induced mitochondrial Ca\(^{2+}\) uptake \[81,82\].

mPTP is a multiprotein complex consisting of the VDAC located in the outer membrane of mitochondria, ANT located in the inner membrane of mitochondria, and matrix protein cyclophilin D (CypD). VDAC and ANT form contact sites on the outer mitochondrial membrane (OMM) and IMM. Other proteins, including hexokinase \[83\], the mitochondrial benzodiazepine receptor \[84\], Bax \[85\], and CK \[86\] are typically associated with and regulate IMM and OMM. ANT is considered to be the key to opening mitochondrial permeability transition pore \[87\]. However, it has been found that ANT deficiency did not block Ca\(^{2+}\)-induced permeability transition \[88\]. VDAC was also considered to be dispensable in Ca\(^{2+}\)-induced MPT and mitochondrial-dependent cell necrosis \[89\]. In contrast, the down-regulation of cyclophilin D was found to be critical for MPT-mediated cell necrosis \[90\]. CypD is the most well characterized regulator of mPTP. mPTP inhibition by targeting CypD protects mouse cells against the death response to specific diseases \[90–93\]. Growing evidence shows that CypD is a regulator of mitochondrial Ca\(^{2+}\) and participates in the regulation of mitochondrial Ca\(^{2+}\) homeostasis through low conductance PTP opening. CypD initiates mitochondrial depolarization by activating low-conductivity PTP, generating Ca\(^{2+}\) waves that release Ca\(^{2+}\) from one mitochondrion to another \[94\]. CypD-deficient mice have been shown to have higher matrix Ca\(^{2+}\) levels, which may be related to the decreased opening of mPTP \[95\]. Cyclosporine A inhibits PTP opening by binding to matrix CypD, thus preventing PTP from binding to ANT. Studies have shown that mPTP is a node of cell death, and functions by integrating the energy metabolism and cell-death mechanism.

4. Mitochondrial Ca\(^{2+}\) Homeostasis and Mitochondrial ROS Emission

ROS are defined as molecules or ions formed by the incomplete one-electron reduction of oxygen. Free radicals, such as superoxide, hydroxyl radical, and singlet oxygen, and non-radical species, such as hydrogen peroxide, are ROS. Mitochondria are the main region of ROS generation. Oxygen free radicals are highly reactive and can damage cellular components such as proteins, lipids, and nucleic acids. During electron transport, electrons may leak from the reducing element of the respiratory chain and react with oxygen to form ROS. ROS play an important role in cell-signal transmission \[96\] but more in the generation of oxidative stress \[96\]. The imbalance between ROS production and ROS detoxification causes mitochondrial oxidative stress. Regulating ROS production is beneficial to signal transduction and other physiological functions. However, if ROS production is not regulated, they can cause oxidative stress, cell damage, and ultimately cell death. The ETC complexes I and III produce superoxide anion radicals during respiration, which are then decomposed into hydrogen peroxide (H\(_2\)O\(_2\)) by Mn\(^{2+}\)-dependent superoxide dismutase \[97–100\]. Glutathione peroxidase (GPX) and thioredoxin/peroxiredoxin systems detoxify H\(_2\)O\(_2\) using reduced NADPH (from NADP-dependent isocitrate dehydrogenase and nicotinamide nucleotide transhydrogenase). Isocitrate dehydrogenase and nicotinamide nucleotide transhydrogenase control the regeneration of NADPH in the TCA cycle \[101,102\]. Glutathione redox conjugate (GSH/GSSG) is the main redox buffer; GSH is a cysteine-containing tripeptide that can directly scavenge ROS or act as a cofactor of glutathione peroxidase. Glutathione peroxidase oxidizes glutathione to reduce H\(_2\)O\(_2\). Additionally, Ca\(^{2+}\) has been reported to activate catalase and GSH reductase, interact with calmodulin (CaM), and then interact with enzymes involved in ROS homeostasis or the
release of GSH in the early stage of PTP opening [21,103]. Furthermore, Ca²⁺ stimulates the TCA cycle and oxidative phosphorylation by increasing respiration rate, thereby enhancing ROS production at the respiratory chain complex [104]. It has been suggested that Ca²⁺ may also indirectly lead to ROS production and can activate nitric oxide synthase to produce NO and inhibit complex IV [105]. In addition, Ca²⁺ activated PTP may inhibit complex III due to the dislocation and loss of cytochrome C. Both Ca²⁺ and cytochrome c compete for cardiolipin binding sites, disrupting electron transfer and increasing ROS production [106]. Therefore, Ca²⁺ enhances ROS production by increasing respiratory rate and reducing substrate concentration. Moreover, Ca²⁺ also activates VDAC [107]. Therefore, mitochondrial Ca²⁺ can induce the TCA cycle, balance energy supply and demand, and can enhance oxidative stress. It has been reported that ROS production in isolated mitochondria increases after PTP activation, despite the requisite mitochondrial uncoupling [108]. The opening of PTP (triggered by Ca²⁺) is believed to cause conformational changes in complex I such that when electrons are provided to complex I, H₂O₂ formation increases, and the passage of electrons through complex I may be inhibited [109]. Another important role of the PTP opening is to produce antioxidant capacity and prevent the release of H₂O₂ [25]. The physiologically stable state of cardiac mitochondria is an intermediate redox state. The intermediate redox state prevents excessive ROS generation in the ETC under high reduction conditions [110,111] and prevents the loss of antioxidant capacity under high oxidation conditions [25,112–114]. In addition, there are other sources of ROS production in mitochondria. A-ketoglutarate dehydrogenase complex (KGDHC) plays a special role in Ca²⁺-induced mitochondrial ROS production [115]. Furthermore, Ca²⁺ has been shown to activate ROS production through isolated KGDHC [116] and other well-known mitochondrial free calcium concentration ([Ca²⁺]ₘ)-regulated TCA cycle enzymes (isocitrate dehydrogenase, α-ketoglutarate dehydrogenase, and pyruvate dehydrogenase) [104]. In addition, ROS may play a necessary role in regulating Ca²⁺ signaling. Just as Ca²⁺ plays a role in ROS production, cellular redox states can significantly modulate Ca²⁺ signaling [114]. ROS can oxidize and regulate ryanodine receptors (RyR), inositol 1,4,5-triphosphate receptors (IP₃R) channels, SERCA, plasma membrane Ca²⁺-ATPase (PMCA), NCX, and other Ca²⁺ transporters [114]. Therefore, the mechanism of the mitochondrial Ca²⁺ regulation of mitochondrial ROS production is important, and the bidirectional regulation mechanism between them must be studied further.

5. Mitochondrial Ca²⁺ Signaling and Autophagy

An increasing number of studies have shown that mitochondrial Ca²⁺ signaling plays a fundamental role in autophagy regulation [117–119]. Recently, mitochondrial Ca²⁺ has been identified as a potential specific signal regulating mitophagy [120]. It has been reported that the downregulation of ER to mitochondrial Ca²⁺ transfer can effectively decrease Parkin-mediated mitophagy [121]. Several studies have elucidated the relationship between mitochondrial Ca²⁺ signaling and autophagy/mitophagy through the cell model of mitochondrial diseases [122]. The dysregulation of Ca²⁺ in MAMs leads to abnormal autophagy [123]. The disruption of Ca²⁺ signaling between the ER and mitochondria can interfere with cell bioenergy and induce autophagy [120]. Studies have shown that mtul loss leads to ER-MITO decoupling, resulting in Ca²⁺ homeostasis imbalance, mitochondrial fragmentation, and mitophagy [124]. MAM is a platform that facilitates the formation of autophagy. Studies have shown that IP₃Rs can transfer Ca²⁺ to mitochondria, activating the core metabolic pathways, as well as increasing the sensitivity of apoptosis and inhibiting basic autophagy [125]. The interruption of Ca²⁺ transport from ER to mitochondria causes adenosine 5’-monophosphate (AMP)-activated protein kinase (AMPK) translocation to MAM and the activation of autophagy through Beclin-1 (BECN) [123]. Some studies have explored the correlation between mitochondrial Ca²⁺ uptake and autophagy. Muscle-restricted
silencing of MCU inhibited mitochondrial Ca\(^{2+}\) and partly inhibited autophagy flux. In addition, the deletion of Atg7, an essential autophagy gene in the skeletal muscle, leads to the accumulation of dysfunctional mitochondria and greatly reduces the accumulation of mitochondrial Ca\(^{2+}\). Thus, reduced MCU activity blocks autophagy flux, and the loss of autophagy further damages mitochondrial Ca\(^{2+}\) signaling, leading to a vicious cycle [126]. Furthermore, MCU-regulator 1 (MCUR1) is a key component of the mitochondrial Ca\(^{2+}\) transport channel complex responsible for mitochondrial Ca\(^{2+}\) uptake. Loss in MCUR1 has been shown to disrupt phosphorylation, reduce intracellular ATP, and activate AMP kinase-dependent pro-survival autophagy [127]. Previous studies have shown that ITPR-mediated Ca\(^{2+}\) transport disruption stimulates autophagy [128]. The overexpression of vesicle-associated membrane protein-associated protein B (VAPB) or microtubule dynamics regulator 3 (RMDN3) enhances ER and mitochondrial contact. Additionally, VAPB-RMDN3 regulates autophagy by promoting Ca\(^{2+}\) exchange between the ER and mitochondria. The inhibition of Ca\(^{2+}\) exchange between ER and mitochondria by ITPR antagonists or siRNA-targeting MCU can eliminate the effects of VAPB and RMDN3 overexpression on autophagy [129]. Therefore, it is increasingly evident that mitochondria play a fundamental role in Ca\(^{2+}\) homeostasis and autophagy regulation in cells.

6. Mitochondrial Ca\(^{2+}\) Uniporter (mtCU) Protein Complex and Mitochondrial Ca\(^{2+}\) Homeostasis

High cytoplasmic Ca\(^{2+}\) microdomains is a prerequisite for mitochondrial Ca\(^{2+}\) uptake [130], and some researchers have found that Ca\(^{2+}\) uptake occurs due to the activation of pathways that may not lead to local increases in the cytoplasmic Ca\(^{2+}\) concentration [131]. Although the physiological and pathological significance of Ca\(^{2+}\) signaling pathways have been debated, recent studies have found that mitochondrial Ca\(^{2+}\) uptake and release mechanisms are central to cellular Ca\(^{2+}\) homeostasis [132,133]. VDAC and mitochondrial calcium monopporter (MCU) are two main channels that mediate Ca\(^{2+}\) influx into mitochondria [40,41,134]. VDAC is a mitochondrial outer-membrane protein responsible for the transport of Ca\(^{2+}\) to the intermembrane space. Subtypes of VDAC include VDAC1, VDAC2, and VDAC3. Of these, VDAC1 has been studied most, while information on VDAC2 and VDAC3 is limited [52], and VDAC1 has high Ca\(^{2+}\) permeability, which permits Ca\(^{2+}\) to enter and leave the mitochondria, affecting various processes of the cell [135]. Furthermore, VDAC1 plays an important role at the junction of mitochondria and endoplasmic reticulum, promoting the entry of Ca\(^{2+}\) from ER into mitochondria and regulating the death pathway of apoptotic cells. As early as the 1960s, mitochondria were identified to be organelles with the ability to accumulate Ca\(^{2+}\) [136,137]. Vasington and Murphy first demonstrated the ability of mitochondria to accumulate Ca\(^{2+}\) in the early 1960s and speculated that mitochondrial Ca\(^{2+}\) accumulation depended on respiration and phosphorylation [137].

Over the past decade, there have been several major discoveries in the understanding of the components of Ca\(^{2+}\) transport systems. In 2009, Ca\(^{2+}\)/H\(^{+}\) exchangers (letm1) were first discovered [138]. A year later, mitochondrial Ca\(^{2+}\) uptake 1 protein (MICU1) [139], which regulates the entry of Ca\(^{2+}\) into mitochondria, and NCX [140], which mediates the release of Ca\(^{2+}\) from mitochondria, were discovered. In 2011, two research groups found that the Ca\(^{2+}\) channel protein subunit MCU, responsible for Ca\(^{2+}\) entry into mitochondria, is sensitive to ruthenium red [40,41]. In the following two years, more regulators of Ca\(^{2+}\) entry into mitochondria, including mitochondrial calcium uniporter dominant negative β (MCUb), MICU2, MCUR1, essential MCU regulator (EMRE), and Solute carriers—solute carrier 25A23 (SLC25A23) (Mg\(^{2+}\)/ATPPi Porter), were discovered [129,141–144]. These findings suggest that the uptake of Ca\(^{2+}\) by mitochondria is mediated by a macromolecular structure, now known as the mitochondrial Ca\(^{2+}\) uniporter (mtCU), which can be inhibited by lanthanide or ruthenium red [65]. In mammals, the uniporter complex is composed of four core components—pore-forming MCU, gatekeeper MICU1, and MICU2, and auxiliary EMRE subunits necessary for calcium transport [145]. Recently, the cryo-EM structure of human mtCU holocomplex in low/high-Ca\(^{2+}\) conditions was reported [146,147]. The
which forms a Ca\textsuperscript{2+} transient. Transient calcium ions promote the binding of Ca\textsuperscript{2+} (i.e., excitation metabolism coupling). However, the importance of mitochondrial Ca\textsuperscript{2+} can also be released through the Na\textsuperscript{+}/Ca\textsuperscript{2+} or Ca\textsuperscript{2+}/H\textsuperscript{+} exchanger [148]. The uptake of Ca\textsuperscript{2+} is driven by the mitochondrial membrane potential, and is electrically neutral in the release of proton exchange or sodium [149]. When intracellular Ca\textsuperscript{2+} concentration increases, mitochondria can accumulate considerably larger amounts of Ca\textsuperscript{2+} under pathological conditions. It has been found that the mitochondrial Ca\textsuperscript{2+} flow regulates the spontaneous electrical activity of ventricular myocytes [150]. Additionally, Ca\textsuperscript{2+} plays a key role in the excitation–contraction coupling of the myocardium [28] and flows into the cytoplasm from the extracellular space through voltage-gated L-type Ca\textsuperscript{2+} channels, triggering the opening of RyR2 on the SR toward the t-tubules, promoting the release of Ca\textsuperscript{2+} in the SR (i.e., Ca\textsuperscript{2+} induced Ca\textsuperscript{2+} release), thus causing the transient increase in the intracellular calcium concentration, which is called “calcium transient”. Transient calcium ions promote the binding of Ca\textsuperscript{2+} to troponin C, which triggers cardiac contraction. Elevated cytoplasmic Ca\textsuperscript{2+} enter the SR cavity through the SERCA or are pumped out of the cell via NCX [132]. Increased Ca\textsuperscript{2+} cycling is associated with increased ATP consumption. Increasing evidence suggests that the transient increase in [Ca\textsuperscript{2+}]m of myocardial mitochondrial Ca\textsuperscript{2+} uptake on the mitochondrial matrix acts as a regulatory signal to ensure the balance of energy supply and demand (i.e., excitation metabolism coupling). However, the importance of mitochondrial Ca\textsuperscript{2+} buffering capacity, the kinetics of mitochondrial Ca\textsuperscript{2+} uptake/release, and the molecular mechanism of [Ca\textsuperscript{2+}]m-mediated ATP and ROS production remain controversial.

Previous studies have revealed that cardiomyocytes promote mitochondrial Ca\textsuperscript{2+} influx through mitochondrial Ca\textsuperscript{2+} channels and transporters [132,151]. In the heart, the main component of Ca\textsuperscript{2+} influx is the MCU complex, and the main complex mediating mitochondrial Ca\textsuperscript{2+} efflux is the mitochondrial NCX. However, it is generally accepted that myocardial cells primarily uptake Ca\textsuperscript{2+} through MCU complexes [152]. The MCU complex is an important regulator of [Ca\textsuperscript{2+}]m and plays an important role in regulating mitochondrial Ca\textsuperscript{2+} homeostasis [153]. The MCU gene was first discovered and reported in 2011 [41]. The highly conserved MCU (CCDC109a) gene encodes the 40 kDa mtCU, which forms a Ca\textsuperscript{2+} channel in mitochondria and exists in almost all eukaryotes except for some protozoa and fungi [154]. MCU consists of two helical domains (CC) and two transmembrane domains connected by a short loop (9 amino acid residues) containing a highly conserved dimer motif [40,41]. The N-terminal and C-terminal of the protein extend for some protozoa and fungi [154]. MCU consists of two helical domains (CC) and two transmembrane domains connected by a short loop (9 amino acid residues) containing a highly conserved dimer motif [40,41]. The N-terminal and C-terminal of the protein extend for some protozoa and fungi [154].

Previous studies have revealed that changes in MCU expression or activity in non-cardiomyocytes have no effect on the mitochondrial membrane potential, oxygen consumption, ATP production, and mitochondrial morphology [155]. Subsequent studies revealed that the MCU complex was primarily responsible for mitochondrial Ca\textsuperscript{2+} influx, and MCU knockdown reduced mitochondrial Ca\textsuperscript{2+} uptake, while MCU overexpression restored mitochondrial Ca\textsuperscript{2+} uptake in knockdown cells [156–158]. Unlike MCU, MCUb has been reported to be an endogenous negative regulatory subunit of the MCU complex [141]. MCUb forms a heterooligomer with MCU, and the binding of MCUb to MCU reduces the Ca\textsuperscript{2+} permeability of the MCU complex [141,143]. Moreover, the overexpression or knockdown of MCUb and subsequent changes in the ratio of MCUb:MCU lead to a significant decrease or increase, respectively, in Ca\textsuperscript{2+} in mitochondria [159]. In addition to MCUb, some auxiliary subunits of MCU complexes have also been discovered, including mitochondrial Ca\textsuperscript{2+} uptake 1 protein (MICU1) [139], MICU2 [142], MICU3 [142], EMRE [143], and MCU-
regulator 1 (MCUR1) [127]. Recent studies have revealed that MCUb can replace MCU to regulate the stoichiometry of miCU and has important effects on mitochondrial Ca\(^{2+}\) uptake and cellular physiology [160]. The overexpression of MCUb can reduce the infarct size caused by IR injury [160]. Furthermore, MICU1 is the first auxiliary subunit of the MCU complex. Previous studies have revealed that MICU1 has a regulatory function and acts as a gatekeeper in the MCU complex. Additionally, MICU1 keeps the MCU pore closed under normal conditions [160], while MICU1 knockdown increases the basal mitochondrial Ca\(^{2+}\) level [161], and even in the case of low cytoplasmic Ca\(^{2+}\) level, MICU1 silencing leads to constitutive mitochondrial Ca\(^{2+}\) overload [127,162]. However, some studies have revealed that MICU1 knockdown inhibits mitochondrial Ca\(^{2+}\) uptake, suggesting that MICU1 plays a positive regulatory role in the MCU pore [139,163]. Similar to MICU1, MICU2 is also considered a gatekeeper. Whether MICU1 or MICU2 plays the predominant role in gatekeeping is still controversial [155]. In the heart, MICU1 expression is relatively low, whereas MICU2 expression in the heart is higher than that in other organs, suggesting that MICU2 plays a more important role than MICU1 in the physiological and pathological conditions of the heart [132]. Furthermore, MICU2 deletion was found to prolong Ca\(^{2+}\) removal and the diastolic time of cardiomyocytes, presenting with mild diastolic dysfunction in vivo [164]. Another important auxiliary subunit in the MCU complex is EMRE, which is considered as a bridge between MCU and MICU1/2. It transmits cytosolic free calcium concentration ([Ca\(^{2+}\)]\(_{c}\)) changes to the MCU complex and activates mitochondrial in situ Ca\(^{2+}\) uptake [143,165]. EMRE has been proposed to be a [Ca\(^{2+}\)] sensor on the matrix side [166]. Furthermore, MCUR1 is a regulatory protein of the MCU complex. Some studies have revealed that MCUR1 is the scaffold protein of the MCU complex, which is essential for cell bioenergy and function [127,167]. Shoubridge et al. showed that MCUR1 knockout inhibits the activity of the ETC by reducing the assembly and activity of cytochrome C oxidase (complex IV), suggesting that the effect of MCUR1 gene knockout on MCU activity may be indirectly affected by changes in the mitochondrial membrane potential [168,169]. In summary, the MCU complex is the main means of mitochondrial Ca\(^{2+}\) uptake in various cells/tissues, including adult ventricular myocytes/hearts. Induced cardiomyocytes isolated from MCU knockout mice were found to still uptake Ca\(^{2+}\). The expression of MCU was reduced to 20%, and mitochondrial Ca\(^{2+}\) uptake was almost completely lost (10–20% of adult ventricular myocytes in the control group). Moreover, the further treatment of MCU knockout cardiomyocytes with Ru360, which is an inhibitor of MCU, did not further inhibit the residual mitochondrial Ca\(^{2+}\) uptake, suggesting that MCU is not the only mechanism that mediates mitochondrial Ca\(^{2+}\) uptake in cardiomyocytes [157]. The MCU has recently been shown to be a redox sensor whose activity increases following oxidation. Furthermore, Cys-97 plays a unique role in ROS sensing and MCU activity regulation. The oxidation of MCU-Cys-97 promotes the formation of its oligomer, resulting in sustained MCU channel activity, enhanced [Ca\(^{2+}\)]\(_{m}\) uptake rate, increased mtROS, and enhanced cell death induced by [Ca\(^{2+}\)]\(_{m}\) overload [170]. In heart disease, the decrease in Ca\(^{2+}\) transient amplitude and the increase in cytoplasmic Na\(^{+}\) play an important role in decreasing mitochondrial Ca\(^{2+}\) [48]. The increase in mitochondrial Ca\(^{2+}\) observed with isolated mitochondria may be due to the increase in MCU activity due to its post-translational modification. It has been shown that α-adrenergic stimulation of ROS/Ca\(^{2+}\)-dependent proline-rich tyrosine kinase Pyk2 translocates from the cytosol to mitochondria, promoting the formation of a tetramer MCU pore and accelerating the uptake of Ca\(^{2+}\) by mitochondria [159]. Therefore, other mechanisms of mitochondrial Ca\(^{2+}\) influx need to be further studied.

### 7. Other Mitochondrial Ca\(^{2+}\) Influx Mechanisms on Mitochondrial Ca\(^{2+}\) Homeostasis

Before the discovery of the MCU complex, several different types of mitochondrial Ca\(^{2+}\) uptake mechanisms were investigated using various experimental methods [171]. Skeletal muscle type RyR type 1 (RyRI) is expressed in the mitochondrial membrane and plays a role in Ca\(^{2+}\) uptake in cardiomyocytes [172]. Investigations of the regulatory effect of mitochondrial RyRI on mitochondrial morphology/function of cardiomyocytes revealed
that transient or stable RyR1 overexpression was partially localized in mitochondria. In addition, the overexpression of RyR1 instead of MCU or RyR2 led to mitochondrial fragmentation [173]. These results suggest that RyR1 possesses mitochondrial localization signals that regulate mitochondrial morphology and Ca\textsuperscript{2+}-induced ATP production in cardiac H9c2 myoblasts [173]. Other mechanisms of mitochondrial Ca\textsuperscript{2+} uptake include rapid uptake mode (RAM) [174,175], Ca\textsuperscript{2+}-selective conductivity (mCa1 and mCa2) [176–178], leucine zipper EF-hand containing transmembrane protein 1 (letm1) [125] and coenzyme Q10 [179]. Additionally, mCa2, RAM, and RyR1 in cardiomyocyte mitochondria may mediate mitochondrial Ca\textsuperscript{2+} uptake through MCU-independent pathways possibly involving different molecular mechanisms [132].

Furthermore, Ca\textsuperscript{2+} is also thought to be transported into mitochondria by proteins other than Ca\textsuperscript{2+} uniporter, including uncoupling proteins 2 and 3 (UCP2 and UCP3) [180]. Uncoupling proteins (UCPs), embedded in the inner membrane of mitochondria, belong to the mitochondrial ion transport superfamily [181]. Accumulating evidence suggests that UCP2 and UCP3 play roles in many cellular processes, including mitochondrial free-radical production, apoptosis, the regulation of hormone secretion, and glucose and fatty acid metabolism. Due to the processes of overexpression, knockdown and mutation of UCP2 and UCP3, it has been found that they are elementary for mitochondrial Ca\textsuperscript{2+} sequestration and are essential for mitochondrial Ca\textsuperscript{2+} uptake [182]. It has also been suggested that UCP2/3 expression levels are critical to the ability of mitochondria to sequester entering Ca\textsuperscript{2+} [183]. Studies have shown that UCP3 acts as a complex molecular switch with different sensitivities to high and low levels of Ca\textsuperscript{2+}. Its contribution to mitochondrial Ca\textsuperscript{2+} uptake depends on the intermembrane loop 2 (IML2) [184]. A subsequent article by Waldeck-Weiermair et al. provided further insight into the role of UCP2 and UCP3 in mitochondrial Ca\textsuperscript{2+} homeostasis. They found that the down-regulation of UCP2 and UCP3 only reduced the mitochondrial Ca\textsuperscript{2+} uptake of intracellularly released Ca\textsuperscript{2+} in response to histamine, a mobilization agonist of inositol-1,4,5-triphosphate (IP3). Therefore, the significant contribution of UCP2 and UCP3 to mitochondrial Ca\textsuperscript{2+} uptake depends on the source and pathway of the increase in intracellular Ca\textsuperscript{2+} [183,184]. Subsequent electrophysiological analyses have shown that UCP2 and UCP3 regulate MCU-dependent Ca\textsuperscript{2+} currents in mitoplasts [185], and these findings are further supported by other groups, these studies suggest that UCP2 is involved in the mitochondrial Ca\textsuperscript{2+} uptake current in mitoplasts of mouse cardiomyocytes [176,178]. However, subsequent studies have shown that UCP3 is not a mitochondrial Ca\textsuperscript{2+} uniporter, and instead negatively regulates SERCA activity by limiting mitochondrial ATP production [186]. UCP2 is thought to play a neuroprotective role by stimulating mitochondrial biogenesis and preventing cell death by reducing membrane potential and calcium influx into mitochondria [187]. Phenotypes of UCP2 knockout mice showed increased susceptibility to Ca\textsuperscript{2+}-mediated ventricular arrhythmias, suggesting that UCP2 plays an important role in cardiac electrophysiology [188].

8. MAMs and Mitochondrial Ca\textsuperscript{2+} Homeostasis

ER is the main storage site of Ca\textsuperscript{2+} in cells [189]. ER and mitochondria play an important role in the transmission of Ca\textsuperscript{2+} signals in physiological and pathological processes [190]. In the 1950s, early signs of a link between the ER and mitochondria were described [191]. In recent years, a physical coupling between mitochondria and ER, called MAM, has been discovered [192]. The number, length, and thickness of the ER in contact with mitochondria are important parameters in determining MAM function [193]. MAM dysfunction is associated with disturbances in calcium homeostasis, phospholipid metabolism, mitochondrial functions, and dynamics [193]. The importance of MAM in Ca\textsuperscript{2+} homeostasis has been established [194]. MAM is a specific microdomain of Ca\textsuperscript{2+} transfer. Cardiomyocyte mitochondria are closely related to the SR. MAM is a dynamic structure that promoted efficiency in the Ca\textsuperscript{2+} transfer from ER to mitochondria. Several proteins are involved in Ca\textsuperscript{2+} transmission [195]. MAM is a complex formed by the precise regulation of Ca\textsuperscript{2+} exchange between ER and mitochondria through the recruitment
of different mitochondria-related proteins and plays an important role in maintaining mitochondrial Ca\(^{2+}\) homeostasis and ultimately regulating the function and survival of cells [196] (Figure 3). The proteins involved in Ca\(^{2+}\) transport in MAM include the ER Ca\(^{2+}\) releasing protein, mitochondrial outer membrane-associated protein, and mitochondrial inner membrane-associated protein [197]. Furthermore, Ca\(^{2+}\) efflux from the ER reaches the mitochondrial matrix through VDAC channels on the OMM and accumulates in the mitochondrial matrix through MCU complexes. The MAM chaperone glucose-regulated protein 75 (GRP75) links the Ca\(^{2+}\) efflux of ER with VDAC1 on the OMM to regulate mitochondrial Ca\(^{2+}\) uptake [198]. Therefore, GRP75 is the bridge connecting IP3R and VDAC1 [199]. Studies have revealed that when the expression of GRP75 in cells is reduced, the functional coupling between ER and mitochondria is eliminated, and the uptake of Ca\(^{2+}\) is affected. This indicates that GRP75 plays an important role in Ca\(^{2+}\) communication between ER and mitochondria [200]. An important element is IP3R, which is an inositol triphosphate-dependent Ca\(^{2+}\) channel located on the ER membrane that controls the outflow of Ca\(^{2+}\) from ER into the cytoplasm. It forms the IP3R-GRP75-VDAC1 complex with IP3R and VDAC1 [201]. VDAC is a mitochondrial outer membrane protein, which together with MCU, regulates Ca\(^{2+}\) influx into mitochondria. The protein complex is responsible for Ca\(^{2+}\) transfer from ER to mitochondria [200, 201]. It has been reported that Ca\(^{2+}\) transport to mitochondria requires an MCU known as the IP3R-GRP75-VDAC-MCU Ca\(^{2+}\) regulatory axis [194, 201]. Because mitochondrial Ca\(^{2+}\) is a key regulator involved in many biological functions, the IP3R-GRP75-VDAC-MCU complex may play an important regulatory role in various cellular functions. It has recently been shown that proteins such as transglutaminase type 2 (TG2) [199], CypD, and DJ-1 [202] interact with the IP3R-GRP75-VDAC1 complex to regulate Ca\(^{2+}\) transfer from ER to mitochondria. Studies have revealed that CypD, as a member of the ER and mitochondrial contact site VDAC1-GRP75-IP3R1 complex, promotes Ca\(^{2+}\) transfer in the two organelles, inhibits CypD, IP3R, and GRP75, reduces protein interactions in the complex, and slows down mitochondrial Ca\(^{2+}\) overload. It is suggested that mitochondrial Ca\(^{2+}\) uptake plays an important role in cardiac ischemia-reperfusion injury and can be used as a target for cardiac protection [203]. Phosphofurin acidic cluster sorting 2 protein (PACS-2) is a multifunctional cytoplasmic protein that induces apoptosis [204, 205]. However, whether PACS-2 can directly attach to MAM is not clear. The loss of PACS-2 has been reported to reduced ER-mitochondrial contact and mitochondrial fragmentation [204]. Sigma non-opioid intracellular receptor 1 (SigR1) and tespa1 are also important proteins that bind the IP3R-GRP75-VDAC-MCU calcium channel on MAM. Furthermore, SigR1 overexpression increases Ca\(^{2+}\) efflux from ER by interacting with ankyrin and the ER chaperone protein BiP [206, 207]. Tespa1 regulates Ca\(^{2+}\) levels by binding to IP3R and GRP75. The knockdown of Tespa1 reduces mitochondrial and cytoplasmic Ca\(^{2+}\) levels [208]. The Fun14 domain containing 1 (FUNDC1) is another protein that regulates the dynamics of MAM [209]. While IP3R2 binds FUNDC1 to regulate SR Ca\(^{2+}\) release [210], FUNDC1 competitively binds DRP1 during early hypoxia. In the late stage of hypoxia, FUNDC1 separates from calnexin and binds DRP1, leading to mitochondrial fission and mitophagy [211]. Presenilin (PS) is a multifunctional protein whose mutation leads to familial Alzheimer’s disease [212]. PS interacts with MFN2 to regulate MAM under Ca\(^{2+}\) overload. The PS2 gene mutation affects mitochondrial Ca\(^{2+}\) delivery [213, 214]. In conclusion, MAM plays an important role in mitochondrial Ca\(^{2+}\) overload and cell necrosis.
the late stage of hypoxia, FUNDC1 separates from calnexin and binds DRP1, leading to mitochondrial fission and mitophagy [211]. Presenilin (PS) is a multifunctional protein whose mutation leads to familial Alzheimer’s disease [212]. PS interacts with MFN2 to regulate MAM under Ca$^{2+}$ overload. The ps2 gene mutation affects mitochondrial Ca$^{2+}$ delivery [213,214]. In conclusion, MAM plays an important role in mitochondrial Ca$^{2+}$ overload and cell necrosis.

Figure 3. Mitochondria-associated membrane (MAM) protein complex regulating Ca$^{2+}$ in cardiomyocytes. There are many MAM complexes between the endoplasmic reticulum (ER) and mitochondria. The IP3R2-Grp75-VDAC complex is an important MAM complex. The Grp75 acts as a bridge between IP3R2 on ER and voltage-dependent anion channel 1 (VDAC1) on the mitochondrial outer membrane to regulate mitochondrial Ca$^{2+}$ uptake. ER protein sigma-1 receptor (Sig-1R) is a Ca$^{2+}$ sensitive and ligand-operated receptor chaperone located in MAM. The Sig-1Rs form a complex with another molecular chaperone BiP on MAM. The Ca$^{2+}$ in ER is depleted or stimulated by ligands, Sig-1R is separated from BiP, producing a prolonged Ca$^{2+}$ signal into mitochondria-dependent on IP3Rs. The increased expression of Sig-1Rs can counteract the ER stress response, while the decrease in Sig-1Rs can enhance apoptosis. Mitochondrial GTPase mitofusin (MFN2) is enriched in the MAM and is also located in the ER, while MFN2 is an endoplasmic reticulum-mitochondria tether. In the ER, it interacts with mitofusins on mitochondria to form an interorganellar bridge. Sarco/endoplasmic reticulum Ca$^{2+}$-ATPase (SERCA) 2b is located in the ER and is responsible for moving Ca$^{2+}$ from the cytoplasm into the ER. Calnexin (CNX) is a quality control partner of the ER, which interacts with SERCA2b. ER-localized thioredoxin-related transmembrane protein 1 (TMX1) interacts with SERCA2b in a thiol-dependent manner to reduce SERCA activity under oxidative conditions. Ryanodine receptor type 2 (RyR2) channel of the sarcoplasmic reticulum is a Ca$^{2+}$ outflow channel of ER. Its activation results in the release of a large amount of Ca$^{2+}$ by the sarcoplasmic reticulum and the transient increase of cytoplasmic Ca$^{2+}$.

9. Molecular Mechanism Underlying Mitochondrial Calcium Efflux Regulation

The mitochondrial Ca$^{2+}$ efflux mechanism involves the NCX and H$^{+}$/Ca$^{2+}$ exchangers. The kinetic characteristics of mitochondrial Ca$^{2+}$ uptake in different tissues are very similar, but mitochondrial calcium efflux mechanism in these tissues is different, mainly by H$^{+}$/Ca$^{2+}$ exchange in non-excitable tissues such as liver and kidney, and mainly by
Na⁺/Ca²⁺ exchange in excitable cells such as neurons and striated muscles [215,216]. The molecular nature of 2H⁺/Ca²⁺ exchangers remains controversial, but studies have suggested that Letm1 may be a plausible candidate [217]. A previous study showed that silencing Letm1 disrupts Ca²⁺/H⁺ exchange in Drosophila S2 and HeLa cells [138]. On the other hand, mitochondrial Ca²⁺ dynamics are also affected by Letm1 [180]. Letm1 moves these two cations across the membrane in a 1 Ca²⁺/2 H⁺ ratio and is therefore a Ca²⁺/H⁺ antiporter [217]. Some studies have shown the mitochondrial localization of NCX, known as NCLX. NCLX is a 100-kDa dimer protein expressed on the inner membrane of brain and heart mitochondria. Its knockdown or overexpression has been shown to significantly reduce or increase mitochondrial Ca²⁺ efflux [218]. Lungo et al. found that inducible cardiac-specific knockout of NCLX decreases the mitochondrial Ca²⁺ efflux rate, mitochondrial Ca²⁺ overload, increased cell necrosis, and sudden death of the animal, indicating that NCLX is key to the regulation of mitochondrial Ca²⁺ [219]. This is consistent with previous studies suggesting that Ca²⁺ efflux from cardiac mitochondria is dependent on cytosolic Na⁺. NCLX knockout has been found to cause sudden death in mice owing to myocardial dysfunction and heart failure. The cardiac pathologic causes are superoxide production and necrotic cell death caused by mitochondrial Ca²⁺ overload and can be prevented by the inhibition of the activation of mPTP [56]. The overexpression of NCLX in mouse hearts by transgenic methods can effectively remove mitochondrial Ca²⁺, prevent permeability transition, and protect against necrosis and heart failure caused by myocardial ischemia [219].

The opening of mPTP has been shown to promote the balance of cofactors and ions, including Ca²⁺, in the IMM and cause the destruction of mitochondrial membrane potential and ATP production, as well as mitochondrial swelling until the breaking of the OMM [190]. Therefore, mPTP is the main cause of reperfusion injury and an effective target of cardiac protection [220]. mPTP is considered to be involved in Ca²⁺ efflux under physiological and pathological conditions [221]. In adult rat ventricular myocytes, mPTP allows for the dissipation of Ca²⁺ through mitochondrial membrane potential [222]. In addition, cyclophilin D is a known regulator of mPTP. mPTP has been shown to act as a Ca²⁺ valve to limit an increase in myocardial mitochondrial Ca²⁺ in cyclophilin D-deficient mice [95]. In the process of the physiological excitation–contraction coupling of cardiac myocytes, cyclophilin D can stimulate the transient opening of the mPTP pore, promoting Ca²⁺ efflux in addition to the NCLX regulation of metabolism in individual mitochondria [223]. The opening of mPTP promotes Ca²⁺ exchange between mitochondria and matrix, coupled with proton counterflow into matrix space [224]. These studies suggest that mPTP may be important in mitochondrial Ca²⁺ efflux under cardiac physiological and pathological conditions.

10. Mitochondrial Ca²⁺ Dyshomeostasis and Cardiac Pathological Remodeling

Mitochondrial Ca²⁺ plays a dual role in regulating cardiac function. Cardiac mitochondrial Ca²⁺ deficiency can impair mitochondrial function, reduce energy supply, and lead to cell damage or death [225]. In addition to energy supply, mitochondrial Ca²⁺ homeostasis plays an important role in other biological functions of cardiomyocytes. For example, mitochondria can buffer intracellular Ca²⁺ to stimulate cardiac excitation–contraction coupling [226,227]. When this function of mitochondria is damaged, the contractile force of cardiomyocytes is disturbed, leading to cardiac insufficiency [226]. Pathological stress such as ischemia, infarction, and pressure overload can induce excessive Ca²⁺ accumulation in cardiomyocytes and lead to mitochondrial Ca²⁺ overload [228]. The maintenance of mitochondrial Ca²⁺ homeostasis is essential for the survival and function of cardiomyocytes.

The effect of mitochondrial Ca²⁺ on chronic heart failure has been widely studied. Additionally, Ca²⁺ treatment disorders are closely associated with heart failure (HF) [229]. Mitochondrial Ca²⁺ homeostasis disorder is a sign of heart failure [230]. In failing hearts, the impaired reuptake of Ca²⁺ by SR and increased Ca²⁺ leakage through RyR has been shown to result in a decreased amount of intracellular Ca²⁺ transients during excitation, but increased intracellular Ca²⁺ at baseline [231,232]. There is increasing evidence of intra-
cellular Ca\(^{2+}\) overload leading to mitochondrial Ca\(^{2+}\) homeostasis damage, the opening of mPTP, increasing mitochondrial oxidative stress, the collapse of mitochondrial membrane potential, damage to ATP production, necrosis of myocardial cells, and subsequent heart failure in animal models [233]. However, the level of Ca\(^{2+}\) that leads to mitochondrial Ca\(^{2+}\) overload in heart failure and the mechanism by which it manifests heart failure remains to be determined. In addition, whether mitochondria are the main Ca\(^{2+}\) pool in the physiological and pathological process of the heart, is controversial [234]. The damage caused by mtROS has been proven to be the main pathogenic mechanism of heart failure [233]. Studies have shown that damage caused by excessive mtROS is evident in human heart-failure patients and animal models [235,236]. Mitochondrial-targeted active oxygen scavenging is beneficial for heart recovery in the heart failure animal models [236–238]. A series of changes in the energy metabolism and redox state occur during cardiac ischemia-reperfusion injury, including decreased ATP level, increased cytoplasmic phosphate and Ca\(^{2+}\) levels, and increased ROS release [239,240]. These conditions lead to mPTP opening. mPTP opening has been shown to be involved in tissue damage that occurs during reperfusion after ischemia by measuring mitochondrial swelling in intact hearts using radiodeoxyglucose [241]. Furthermore, the presence of antioxidants during reperfusion significantly reduced myocardial injury induced by ischemia-reperfusion, suggesting that oxidative stress is one of the causes of tissue damage underlying these conditions [242].

Some scientists have shown that mitochondrial Ca\(^{2+}\) homeostasis affects the regulatory function of PGC-1\(\alpha\) [243]. It is known that PGC-1\(\alpha\) plays a central role in the regulation of the cardiac energy metabolism by driving coupled respiration and activating mitochondrial biology because PGC-1\(\alpha\) is a member of a family of transcription co-activating factors [244]. Thus, mitochondrial Ca\(^{2+}\) may alter the energy metabolism and signaling within organelles by accumulating, buffering, and releasing Ca\(^{2+}\), leading to diabetic cardiomyopathy [245]. Some scientists used a type 1 STZ-induced diabetic rat model to simulate diabetic patients, and found defects in mitochondrial Ca\(^{2+}\) treatment in the model, resulting in a decreased Ca\(^{2+}\) uptake and ATP synthesis rate [246]. In addition, Tanaka et al. also confirmed a reduction in mitochondrial Ca\(^{2+}\) accumulation in animals injected with STZ [247]. It has also been suggested that the opening of cardiac mitochondrial mPTP in diabetics leads to the release of accumulated Ca\(^{2+}\) [248]. Diaz Juarez et al. reported that cardiomyocytes exposed to high glucose showed decreased mitochondrial Ca\(^{2+}\) levels and dehydrogenase activity, which may be related to low MCU levels. Low rates of mitochondrial Ca\(^{2+}\) uptake have been found in animal models of obesity and type 2 diabetes [249]. Belke et al. also found that in db/db mice, the level of Ca\(^{2+}\) and the decay rate of Ca\(^{2+}\) decreased, indicating impaired mitochondrial Ca\(^{2+}\) uptake [250]. Mitochondrial Ca\(^{2+}\) overload is believed to lead to cardiac dysfunction by promoting the production of mitochondrial ROS and the opening of mPTP, primarily via cardiomyocyte death [158,251,252]. Genetic studies have shown that ANT and the phosphate carrier (PiC) are regulators of mPTP, while F1-F0 ATP synthase is a component of the pores. These three are not only functionally coupled with mitochondrial ATP but also physically coupled with the inner membrane supercomplex called ATP synthasome [253]. The removal of any component of ATP synthase results in mitochondrial oxidative phosphorylation disorder [254,255], which affects energy production [256], leading to a series of heart diseases. ANT1 deficiency has been reported to lead to hypertrophic cardiomyopathy, myopathy, lactic acidosis, and exercise intolerance [257]. Moreover, the knockout of PiC or ANT1 in mouse hearts can lead to severe mitochondrial car-diomyopathy [254,258,259]. Human patients with PiC skeletal muscle subtype mutations have muscle weakness, lactic acidosis, hypertrophic cardiomyopathy, and a shortened lifespan [260].

Because Ca\(^{2+}\) directly inhibits glutathione reductase, the main antioxidant in the matrix, mitochondrial Ca\(^{2+}\) overload also reduces the scavenging ability of mitochondrial ROS [261]. In addition, the excessive production of ROS mediated by mitochondrial Ca\(^{2+}\) leads to the post-translational modification of Ca\(^{2+}\)-handling proteins such as RyR2, and the subsequent disruption of cytoplasmic Ca\(^{2+}\) processing and mPTP opening, ul-
Ultimately leading to cardiomyocyte apoptosis [36]. In myocardial ischemia/reperfusion injury, mitochondrial Ca\(^{2+}\) overload-mediated cardiomyocyte death is due to mitochondrial Ca\(^{2+}\)-dependent mPTP activation [262]. Studies of an induced cardiomyocyte-specific MCU knockout model and NCLX overexpression model suggest that mitochondrial Ca\(^{2+}\) overload is the main mediator of ROS production and mPTP activation which induce ischemia/reperfusion injury and other acute heart diseases [263]. However, some studies have found that reduced mitochondrial Ca\(^{2+}\) leads to oxidative stress and cell damage under cardiac pathological conditions [264]. The intracellular sodium concentration [Na\(^{+}\)]c has been shown to be increased in failing guinea pig hearts relative to [Na\(^{+}\)]c in normal hearts [25,48,265]. NCLX accelerates Ca\(^{2+}\) outflow and reduces [Ca\(^{2+}\)]m in failing hearts [266]. In addition, the pharmacological inhibition of NCLX restored mitochondrial Ca\(^{2+}\) treatment and cell oxidation in adult ventricular myocytes [267]. In a type 1 diabetic mouse model, MCU expression, mitochondrial Ca\(^{2+}\) uptake, and mitochondrial Ca\(^{2+}\) content in adult ventricular myocytes were significantly reduced. In addition, MCU re-expression in diabetic hearts has been found to improve the treatment and metabolism of impaired mitochondrial Ca\(^{2+}\) [268]. The study of the heart-failure model after myocardial infarction in mice showed that RyR2-mediated increased SR-Ca\(^{2+}\) leakage is accompanied by an increase in mitochondrial calcium concentration (Mito-[Ca\(^{2+}\)]), suggesting that mitochondrial Ca\(^{2+}\) overload is a key determinant of heart failure [251]. Xie et al. evaluated the effect of mitochondrial Ca\(^{2+}\) influx on arrhythmia risk in non-ischemic cardiomyopathy and found that the mitochondrial Ca\(^{2+}\) level increased in ventricular myocytes of a non-ischemic heart failure model induced by hypertension in mice [269]. The level of Ca\(^{2+}\) in mitochondria isolated from an aging human heart was found to be increased, which was attributed to the post-translational modification of MCU, which leads to its function becoming impaired under the condition of oxidative stress and increased catecholaminergic tension (such as HF) [270].

11. Targeting Mitochondria: Mitochondrial Ca\(^{2+}\) as Drug Targets in the Treatment of Cardiovascular Diseases

The increased incidence of malignant arrhythmias can contribute to heart failure, diabetic cardiomyopathy, senile cardiac insufficiency, and hereditary diseases [271]. Abnormalities in intracellular Ca\(^{2+}\) homeostasis and mitochondrial dysfunction are considered to be key factors in the pathophysiology of these diseases [272]. Garcia Rivas et al. showed that a perfusion of the MCU inhibitor RU360 could eliminate the incidence of arrhythmias caused by ischemia/reperfusion injury in an open-chest rat model [273]. Thus, the inhibition of MCU prevents mitochondrial Ca\(^{2+}\) overload, the subsequent activation of mPTP and loss of mitochondrial membrane potential. As the MCU complex is not the only pathway for Ca\(^{2+}\) influx, an inhibition of MCU expression/function does not affect basic Mito-[Ca\(^{2+}\)] or substantially affect cardiac function under basic conditions [274]. The increase in mitochondrial ROS has also been associated with arrhythmogenic effects [275].

Studies have shown that drugs targeting mitochondria interfere with mitochondrial Ca\(^{2+}\) transport and Ca\(^{2+}\)-induced membrane permeability transition, inhibit the activation of the MAPK/JNK pathway, inhibit foam-cell formation, and reduce the progression of atherosclerosis [276]. CsA is an inhibitor of mPTP and can bind to CypD, a positive regulator of mPTP. The cardioprotective effect of CsA has been assessed in several reperfusion myocardial infarction model animals, but results regarding a reduction in the infarct size have been inconsistent [277]. In a Phase II trial, CsA in patients with ST-segment elevation MI (STEMI) showed promising results [278,279].

It is promising to develop therapeutic peptides targeting mitochondrial Ca\(^{2+}\) regulation. These peptides primarily include Ca\(^{2+}\) channels and pumps that regulate ER localization and small peptides or proteins that regulate mitochondrial Ca\(^{2+}\) channels, affecting Ca\(^{2+}\) transport from ER to mitochondria (Table 1). Anti-apoptotic Bcl-2 proteins also play an important role in regulating intracellular Ca\(^{2+}\) signaling. Additionally, Bcl-2 binds to the central regulatory region of IP3R through its BH4 domain, inhibiting IP3R-mediated
Ca\(^{2+}\) release. The introduction of the BH4 domain of Bcl-2 (BH4-Bcl-2) as a polypeptide has been shown to inhibit IP3R-mediated Ca\(^{2+}\) release and protect cells from pro-apoptotic Ca\(^{2+}\) transfer to mitochondria [280]. An IP3R-derived peptide, Bcl-2/IP3R disruptor 2 (Bird-2), was established based on the BH4-Bcl-2 binding site in the central regulatory region of IP3R, which is located in a 20-amino acid region [280]. The mechanism of Bird-2 inducing cell death has not been elucidated. In the heart, DHPRs activates RyR by triggering Ca\(^{2+}\)-induced Ca\(^{2+}\) release via Ca\(^{2+}\) influx. Further studies have shown that a short fragment of the cytosolic II–III loop of the DHPR, called peptide A, induces RyR1-mediated Ca\(^{2+}\) release [281]. The lipoamino acid conjugation of peptide A increased its cellular permeability while maintaining its structural and functional properties, making it a potential therapeutic option [282]. Some peptide toxins, called calcins, have similar effects on RyR1 gating [283]. Calcins are short cell-permeable peptides that have a high affinity for RyR1 and specifically bind and stimulate its activity. Moreover, some peptides have been found to regulate mitochondrial Ca\(^{2+}\) uptake by directly or proximally acting on VDAC and MCU. Short peptides from the N-terminal of VDAC1 and LP4 (ANTP-N-TER and ANTP-L14-15, respectively) may significantly inhibit mitochondrial Ca\(^{2+}\) uptake and lung cancer cell migration by blocking the interaction between VDAC1 and Bel-1, McI-1 [284], or HKI. The R-tf-d-lp4 peptide significantly increased intracellular Ca\(^{2+}\) levels, and this event was associated with VDAC1 oligomerization, cytochrome c release, and apoptotic cell death. Peptides derived from accessory protein sequences of VDAC1 show potential therapeutic applications [285]. Furthermore, BH4-Bcl-XL almost completely blocks VDAC1-mediated Ca\(^{2+}\) uptake into mitochondria, making cells more resistant to the pro-apoptotic release of Ca\(^{2+}\) from the MAM-targeted ER [286]. Owing to the effect of BH4-Bcl-XL on VDAC1 and its role as an inhibitor of RyR in ER, it can be used to treat diseases characterized by toxic mitochondrial Ca\(^{2+}\) signaling, such as ischemia-reperfusion injury [287], Alzheimer’s disease [288], and Parkinson’s disease [289]. Studies have shown that B-type natriuretic peptide (BNP) released by cardiomyocytes plays a cardioprotective role by inhibiting MCU and affecting mPTP opening [290]. The recombinant BNP peptide (Nesiritide, Natrecor) has been approved by the FDA for the treatment of acute decompensated congestive heart failure, but its clinical efficacy remains controversial. Some other peptides indirectly affect ER-mitochondrial Ca\(^{2+}\) flux or homeostasis. The fungus-derived cyclic peptide cyclosporine A (CsA) desensitizes mPTP to Ca\(^{2+}\) and inhibits pore opening. In recent years, an increasing number of CypD-selective and non-immunosuppressive derivatives of CsA (such as mCsA, NIM811, and DEBio-025) have been developed as promising cardioprotective agents, as their ability to reduce the harmful effects of acute myocardial infarction has been observed in different models [291]. Another non-immunosuppressive analogue of cyclosporine A is Alisporivir (Ali), which inhibits MPT pore assembly by interacting with cyclosporine D [292]. Studies have shown that Ali, as a mitochondrial targeted metabolic reprogramming agent, can significantly increase Ca\(^{2+}\) retention in diabetic animals, reduce oxidative damage of heart tissue, and improve the glucose utilization rate [293]. More recently, the octapeptide RRNYRRNY (RNY) has been identified as a potential cardiac protective agent that inhibits the connexin 43 (Cx43) hemichannels in mitochondria [294]. Furthermore, Cx43 is a connexin that forms mitochondrial Ca\(^{2+}\) permeable hemichannels, contributing to a mitochondrial Ca\(^{2+}\) overload and loss of energy and ion gradients, leading to cell death [295,296]. RNY can offset the harmful effects of mitochondrial Cx43-HCs through its channel-inhibitory activity, which reduces mitochondrial Ca\(^{2+}\) overload and infarct size during cardiac ischemia-reperfusion [294]. In addition to the targets discussed above, there are many intracellular hot spots for ER-mitochondrial Ca\(^{2+}\) crosstalk that deserve further study. In conclusion, preclinical data using decoy or regulatory peptides acting on major Ca\(^{2+}\) channels in the ER-mitochondria will be needed to facilitate the rapid development of these tools into practical therapies.
Table 1. Inhibitors and peptides that target mitochondrial calcium.

| Name            | Source/Mechanism                                                                 | Proposed Mode of Action                                                                 | References       |
|-----------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------|
| CsA             | an inhibitor of mPTP and can bind to CypD                                       | a positive regulator of mPTP                                                           | [277–279]       |
| mtCsA           | non-immunosuppressive derivatives of CsA desensitizes mPTP to Ca$^{2+}$ and inhibits pore opening |                                                                                         |                 |
| BH4-Bcl-2       | BH4 domain of Bcl-2                                                             | inhibit IP3R-mediated Ca$^{2+}$ release                                                  | [280]           |
| Bcl-2/IP3R disruptor 2 (Bird-2) | an IP3R-derived peptide            | inhibit IP3R-mediated Ca$^{2+}$ release                                                  | [280]           |
| peptide A       | a short fragment of the cytosolic II–III loop of the DHPR                        | induces RyR1-mediated Ca$^{2+}$ release                                                  | [281]           |
| Calcins         | have a high affinity for RyR1 and specifically bind and stimulate its activity. | have similar effects on RyR1 gating                                                     | [283]           |
| ANTP-N-TER      | N-terminal of VDAC1                                                             | significantly inhibit mitochondrial Ca$^{2+}$ uptake                                     | [284]           |
| ANTP-L14-15     | short peptides from the N-terminal of LP4                                        | inhibit mitochondrial Ca$^{2+}$ uptake                                                   | [284]           |
| R-tf-d-lp4 peptide | the VDAC1-based peptide                              | significantly increased intracellular Ca$^{2+}$ levels                                   | [285]           |
| BH4-Bcl-XL      | an inhibitor of RyR in ER                                                         | blocks VDAC1-mediated Ca$^{2+}$ uptake into mitochondria                               | [286–289]       |
| Nesiritide, Natreceor | recombinant BNP peptide                      | inhibiting MCU and affecting mPTP opening                                               | [290]           |
| Octapeptide RRNYRRNY (RNY) | inhibits the Cv43 hemichannels in mitochondria                              | reduces mitochondrial Ca$^{2+}$ overload                                                | [294]           |

Author Contributions: Y.G. conceived of the manuscript. D.Z., F.W. and P.L. drafted the manuscript, constructed the figures, and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by grants from the National Natural Science Foundation of China (Nos. 81602353 and 31870816), Major Research Program of the National Natural Science Foundation of China (No. 91849209), the Natural Science Foundation of Jiangsu Province (BK20171145), the China Postdoctoral Science Foundation (2019M652314 and 2020T130333), the Qingdao Applied Basic Research Project (19-6-2-39-cg), and the Qingdao Science and Technology Plan Fund (18-6-1-63-nsh).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Milane, L.; Trivedi, M.; Singh, A.; Talekar, M.; Amiji, M. Mitochondrial biology, targets, and drug delivery. J. Control. Release Off. J. Control. Release Soc. 2015, 207, 40–58. [CrossRef] [PubMed]
2. Lemieux, H.; Hoppel, C.L. Mitochondria in the human heart. J. Bioenerg. Biomembr. 2009, 41, 99–106. [CrossRef] [PubMed]
3. Ong, S.B.; Kalkhoran, S.B.; Hernandez-Resendiz, S.; Samangouei, P.; Ong, S.G.; Hausenloy, D.J. Mitochondrial Shaping Proteins in Cardiac Health and Disease—The Long and the Short of It! Cardiovasc. Drugs Ther. 2017, 31, 87–107. [CrossRef] [PubMed]
4. Palmer, J.W.; Tandler, B.; Hoppel, C.L. Biochemical properties of subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle. J. Biol. Chem. 1977, 252, 8731–8739. [CrossRef]
5. Kurian, G.A.; Berenshtein, E.; Saada, A.; Chevion, M. Rat cardiac mitochondrial sub-populations show distinct features of oxidative phosphorylation during ischemia, reperfusion and ischemic preconditioning. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Pharmacol. 2012, 30, 83–94. [CrossRef]
6. Hollander, J.M.; Thapa, D.; Shepherd, D.L. Physiological and structural differences in spatially distinct subpopulations of cardiac mitochondria: Influence of cardiac pathologies. Am. J. Physiol. Heart Circ. Physiol. 2014, 307, H1–H14. [CrossRef]
7. Rosca, M.G.; Hoppel, C.L. Mitochondria in heart failure. Cardiovase. Res. 2010, 88, 40–50. [CrossRef]
8. Hoppel, C.L.; Tandler, B.; Fujijika, H.; Riva, A. Dynamic organization of mitochondria in human heart and in myocardial disease. Int. J. Biochem. Cell Biol. 2009, 41, 1949–1956. [CrossRef]
9. Vasiliev, P.V.; Evangelou, K.; Vlasis, K.; Fildisis, G.; Panayiotidis, M.I.; Chronopoulos, E.; Passias, P.G.; Kouloukoussa, M.; Gorgoulis, V.G.; Havaki, S. Mitochondrial Homeostasis and Cellular Senescence. Cells 2019, 8, 686. [CrossRef]
10. Dietl, A.; Maack, C. Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure. Curr. Heart Fail. Rep. 2017, 14, 338–349. [CrossRef]
11. Vasquez-Trincado, C.; Garcia-Carvajal, I.; Pennanen, C.; Parra, V.; Hill, J.A.; Rothermel, B.A.; Lavandero, S. Mitochondrial dynamics, mitophagy and cardiovascular disease. J. Physiol. 2016, 594, 509–525. [CrossRef] [PubMed]
41. De Stefani, D.; Raffaello, A.; Teardo, E.; Szabo, I.; Rizzuto, R. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature 2011, 476, 336–340. [CrossRef] [PubMed]

42. Hansford, R.G.; Zorov, D. Role of mitochondrial calcium transport in the control of substrate oxidation. Mol. Cell Biochem. 1998, 184, 359–369. [CrossRef] [PubMed]

43. McCormack, J.G.; Denton, R.M. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol. Res. 1990, 70, 391–425. [CrossRef] [PubMed]

44. Nichols, B.J.; Rigoulet, M.; Denton, R.M. Comparison of the effects of Ca²⁺, adenine nucleotides and pH on the kinetic properties of mitochondrial NAD⁺-isocitrateg dehydrogenase and oxoglutarate dehydrogenase from the yeast Saccharomyces cerevisiae and rat heart. Biochem. J. 1994, 303 Pt 2, 461–465. [CrossRef]

45. McCormack, J.G.; Denton, R.M. Role of Ca²⁺ ions in the regulation of intramitochondrial metabolism in rat heart. Evidence from studies with isolated mitochondria that adrenaline activates the pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase complexes by increasing the intramitochondrial concentration of Ca²⁺. Biochem. J. 1994, 218, 235–247.

46. Rutter, G.A.; Denton, R.M. Regulation of NAD⁺-linked isocitrateg dehydrogenase and 2-oxoglutarate dehydrogenase by Ca²⁺ ions within toluene-permeabilized rat heart mitochondria. Interactions with regulation by adenine nucleotides and NADH/NAD⁺ ratios. Biochem. J. 1988, 252, 181–189. [CrossRef]

47. Balaban, R.S. Cardiac energy metabolism homeostasis: Role of cytosolic calcium. J. Mol. Cell. Cardiol. 2002, 34, 1259–1271. [CrossRef]

48. Maack, C.; Cortassa, S.; Aon, M.A.; Ganesan, A.N.; Liu, T.; O’Rourke, B. Elevated cytosolic Na⁺ decreases mitochondrial Ca²⁺ uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes. Circ. Res. 2006, 99, 172–182. [CrossRef]

49. Aon, M.A.; Cortassa, S.; Marban, E.; O’Rourke, B. Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes. Circ. Res. 2006, 99, 172–182. [CrossRef]

50. Sampson, M.J.; Lovell, R.S.; Craigien, W.J. The murine voltage-dependent anion channel gene family. Conserved structure and function. J. Biol. Chem. 1997, 272, 18966–18973. [CrossRef] [PubMed]

51. Crompton, M.; Virji, S.; Ward, J.M. Cyclophilin-D binds strongly to complexes of the voltage-dependent anion channel and the adenine nucleotide translocase to form the permeability transition pore. Eur. J. Biochem. 1998, 258, 729–735. [CrossRef] [PubMed]

52. Sheu, S.S.; Nauduri, D.; Anders, M.W. Targeting antioxidants to mitochondria: A new therapeutic direction. Biochim. Biophys. Acta 2006, 1762, 256–265. [CrossRef] [PubMed]

53. Gunter, T.E.; Sheu, S.S. Characteristics and possible functions of mitochondrial Ca²⁺ transport mechanisms. Biochim. Biophys. Acta 2009, 1787, 1291–1308. [CrossRef] [PubMed]

54. Liochev, S.I.; Fridovich, I. Superoxide and iron: Partners in crime. IUBMB Life 1999, 48, 157–161. [CrossRef]

55. Bertero, E.; Maack, C. Calcium Signaling and Reactive Oxygen Species in Mitochondria. Recent Adv. Stud. Card. Struct. Metab. 2018, 122, 1460–1478. [CrossRef]

56. Viola, H.M.; Arthur, P.G.; Hool, L.C. Transient exposure to hydrogen peroxide causes an increase in mitochondria-derived superoxide as a result of sustained alteration in L-type Ca²⁺ channel function in the absence of apoptosis in ventricular myocytes. Circ. Res. 2007, 100, 1036–1044. [CrossRef]

57. Viola, H.M.; Davies, S.M.; Filipovska, A.; Hool, L.C. L-type Ca²⁺ channel contributes to alterations in mitochondrial calcium handling in the mdx ventricular myocyte. Am. J. Physiol. Heart Circ. Physiol. 2013, 304, H767–H775. [CrossRef]

58. Viola, H.M.; Arthur, P.G.; Hool, L.C. Evidence for regulation of mitochondrial function by the L-type Ca²⁺ channel in ventricular myocytes. J. Mol. Cell. Cardiol. 2009, 46, 1016–1026. [CrossRef]

59. Kohlhaas, M.; Nickel, A.G.; Maack, C. Mitochondrial energetics and calcium coupling in the heart. J. Physiol. 2017, 595, 3753–3763. [CrossRef] [PubMed]

60. Cortassa, S.; Aon, M.A.; O'Rourke, B.; Jacques, R.; Tseng, H.J.; Marban, E.; Winslow, R.L. A computational model integrating electrophysiology, contraction, and mitochondrial bioenergetics in the ventricular myocyte. Biophys. J. 2006, 91, 1564–1589. [CrossRef] [PubMed]

61. Stout, A.K.; Raphael, H.M.; Kanterewicz, B.I.; Klann, E.; Reynolds, I.J. Glutamate-induced neuron death requires mitochondrial calcium uptake. Nat. Neurosci. 1998, 1, 366–373. [CrossRef] [PubMed]

62. Fleckenstein, A.; Janke, J.; Doring, H.J.; Leder, O. Myocardial fiber necrosis due to intracellular Ca overload a new principle in cardiac pathophysiology. Recent Adv. Stud. Card. Struct. Metab. 1974, 4, 563–580.

63. Bernardi, P. Mitochondrial transport of cations: Channels, exchangers, and permeability transition. Physiol. Rev. 1999, 79, 1127–1155. [CrossRef]

64. Nieminen, A.L.; Byrne, A.M.; Herman, B.; Lemasters, J.J. Mitochondrial permeability transition in hepatocytes induced by t-BuOOH: NAD(P)H and reactive oxygen species. Am. J. Physiol. 1997, 272 Pt 1, C1286–C1294. [CrossRef]

65. Vercesi, A.E.; Kowaltowski, A.J.; Grijalba, M.T.; Menincke, A.R.; Castillo, R.F. The role of reactive oxygen species in mitochondrial permeability transition. Biosci. Rep. 1997, 17, 43–52. [CrossRef] [PubMed]

66. O'Reilly, C.M.; Fogarty, K.E.; Drummond, R.M.; Tuft, R.A.; Walsh, J.V. Jr. Quantitative analysis of spontaneous mitochondrial depolarizations. Biophys. J. 2003, 85, 3350–3357. [CrossRef]
94. Ichas, F.; Jouaville, L.S.; Mazat, J.P. Mitochondria are excitable organelles capable of generating and conveying electrical and
92. Millay, D.P.; Sargent, M.A.; Osinska, H.; Baines, C.P.; Barton, E.R.; Vuagniaux, G.; Sweeney, H.L.; Robbins, J.; Molkentin, J.D.
78. Giorgi, C.; Romagnoli, A.; Pinton, P.; Rizzuto, R. Ca$^{2+}$
77. Kroemer, G.; Reed, J.C. Mitochondrial control of cell death. Nat. Med.
74. Bernardi, P.; Broekemeier, K.M.; Pfeiffer, D.R. Recent progress on regulation of the mitochondrial permeability transition pore; a
71. Al-Nasser, I.; Crompton, M. The reversible Ca$^{2+}$
91. Ramachandran, A.; Lebofsky, M.; Baines, C.P.; Lemasters, J.J.; Jaeschke, H. Cyclophilin D deficiency protects against
83. Beutner, G.; Ruck, A.; Riede, B.; Brdiczka, D. Complexes between kinases, mitochondrial porin and adenylate
80. Szalai, G.; Krishnamurthy, R.; Hajnoczky, G. Apoptosis driven by IP3-linked mitochondrial calcium signals. Am. J. Physiol. 1990, 258 Pt 1, C755–C786.
[CrossRef] [PubMed]
89. Baines, C.P.; Kaiser, R.A.; Sheiko, T.; Craigen, W.J.; Molkentin, J.D. Voltage-dependent anion channels are dispensable for
88. Kokoszka, J.E.; Waymire, K.G.; Levy, S.E.; Sligh, J.E.; Cai, J.; Jones, D.P.; MacGregor, G.R.; Wallace, D.C. The ADP/ATP translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases. Biochim. Et Biophys. Acta 2002, 1516, 169–178. [CrossRef] [PubMed]
87. Kroemer, G.; Reed, J.C. Mitochondrial control of cell death. Nat. Med. 2000, 6, 513–519. [CrossRef]
86. Beutner, G.; Ruck, A.; Riede, B.; Brdiczka, D. Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate
85. Davison, D.; Brdiczka, D. Complexes between kinases, mitochondrial porin and adenylate translocator in rat brain resemble the permeability transition pore. FEBs Lett. 1996, 396, 189–195. [CrossRef] [PubMed]
84. McEnery, M.W.; Snowman, A.M.; Trifiletti, R.R.; Snyder, S.H. Isolation of the mitochondrial benzodiazepine receptor: Association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc. Natl. Acad. Sci. USA 1992, 89, 3170–3174. [CrossRef] [PubMed]
83. Hayashi, T.; Su, T.P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca$^{2+}$
82. Pieroni, A.; Castiglioni, C.; Giorgi, C.; Romagnoli, A.; Pinton, P.; Rizzuto, R. Ca$^{2+}$
81. Altschuld, R.A.; Hohl, C.M.; Castillo, L.C.; Garleb, A.A.; Starling, R.C.; Brierley, G.P. Cyclosporin inhibits mitochondrial calcium
79. Gunter, T.E.; Pfeiffer, D.R. Mechanisms by which mitochondria transport calcium.
78. Altschuld, R.A.; Hohl, C.M.; Castillo, L.C.; Garleb, A.A.; Starling, R.C.; Brierley, G.P. Cyclosporin inhibits mitochondrial calcium
77. Giorgi, C.; Romagnoli, A.; Pinton, P.; Rizzuto, R. Ca$^{2+}$ signaling, mitochondria and cell death. Curr. Mol. Med. 2008, 8, 119–130.
76. Altschuld, R.A.; Hohl, C.M.; Castillo, L.C.; Garleb, A.A.; Starling, R.C.; Brierley, G.P. Cyclosporin inhibits mitochondrial calcium
75. Gunter, T.E.; Pfeiffer, D.R. Mechanisms by which mitochondria transport calcium.
74. Bernardi, P.; Broekemeier, K.M.; Pfeiffer, D.R. Recent progress on regulation of the mitochondrial permeability transition pore; a
cyclosporin-sensitive pore in the inner mitochondrial membrane. J. Bioenerg. Biomembr. 2000, 32, 333–346. [CrossRef] [PubMed]
73. Vergun, O.; Votyakova, T.V.; Reynolds, I.J. Spontaneous changes in mitochondrial membrane potential in single isolated brain mitochondria. Biophys. J. 2003, 85, 3358–3366. [CrossRef]
72. Al-Nasser, I.; Crompton, M. The entrapment of the Ca$^{2+}$ indicator arsenazo III in the matrix space of rat liver mitochondria by permeabilization and resealing. Na$^{+}$-dependent and -independent effluxes of Ca$^{2+}$ in arsenazo III-loaded mitochondria. Biochem. J. 1986, 239, 31–40. [CrossRef] [PubMed]
71. Al-Nasser, I.; Crompton, M. The reversible Ca$^{2+}$
70. Huser, J.; Blatter, L.A. Fluctuations in mitochondrial membrane potential caused by repetitive gating of the permeability transition pore. Biochem. J. 1999, 343 Pt 2, 311–317. [CrossRef] [PubMed]
96. Brookes, P.S.; Levensen, A.L.; Shiva, S.; Sarti, P.; Darley-Usmar, V.M. Mitochondria: Regulators of signal transduction by reactive oxygen and nitrogen species. Free Radic. Biol. Med. 2002, 33, 755–764. [CrossRef]

97. Murphy, E.; Ardehali, H.; Balaban, R.S.; DiLisa, F.; Dorn, G.W., 2nd; Kitis, R.N.; Otsu, K.; Ping, P.; Rizzuto, R.; Sack, M.N.; et al. Mitochondrial Function, Biology, and Role in Disease: A Scientific Statement from the American Heart Association. Circ. Res. 2016, 118, 1960–1991. [CrossRef]

98. Zorov, D.B.; Juhaszova, M.; Sollott, S. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol. Rev. 2014, 94, 909–950. [CrossRef]

99. Chen, Y.R.; Zweier, J.L. Cardiac mitochondria and reactive oxygen species generation. Circ. Res. 2014, 114, 524–537. [CrossRef]

100. Nickel, A.G.; von Hardenberg, A.; Hohl, M.; Loffler, J.R.; Kohlhaas, M.; Becker, J.; Reil, J.C.; Kazakov, A.; Bonneko, J.; Stadelmaier, M.; et al. Reversal of Mitochondrial Transhydrogenase Causes Oxidative Stress in Heart Failure. Cell Metab. 2015, 22, 472–484. [CrossRef] [PubMed]

101. Ying, W. NADPH/NADP+ in cellular functions and cell death: Regulation and biological consequences. Antioxid. Redox Signal. 2008, 10, 179–206. [CrossRef] [PubMed]

102. Yan, Y.; Wei, C.L.; Zhang, W.R.; Cheng, H.P.; Liu, J. Cross-talk between calcium and reactive oxygen species signaling. Acta Pharmacol. Sin. 2006, 27, 821–826. [CrossRef] [PubMed]

103. Yan, Y.; Li, L.; Cheung, Y.J.; Scaduto, R.C., Jr. Regulation of citric acid cycle by calcium. J. Biol. Chem. 1989, 264, 13430–13439. [CrossRef] [PubMed]

104. Wain, B.; LaNoue, K.F.; Cheung, J.Y.; Scaduto, R.C., Jr. Regulation of citric acid cycle by calcium. J. Biol. Chem. 1989, 264, 593–615. [CrossRef] [PubMed]

105. Alderton, W.K.; Cooper, C.E.; Knowles, R.G. Nitric oxide synthases: Structure, function and inhibition. Biochem. J. 2001, 357 Pt 3, 593–615. [CrossRef] [PubMed]

106. Grijalba, M.T.; Vercesi, A.E.; Schreier, S. Ca2+-induced increased lipid packing and domain formation in submitochondrial particles. A possible early step in the mechanism of Ca2+-stimulated generation of reactive oxygen species by the respiratory chain. Biochemistry 1999, 38, 13279–13287. [CrossRef] [PubMed]

107. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]

108. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]

109. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]

110. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]

111. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]

112. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]

113. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]

114. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]

115. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]

116. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]

117. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]

118. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]

119. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]

120. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]

121. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]

122. Yan, Y.; Piette, J.D.; Orrenius, S.; Scheynius, A. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. J. Biol. Chem. 2006, 281, H1549–H1557. [CrossRef] [PubMed]
124. Puri, R.; Cheng, X.T.; Lin, M.Y.; Huang, N.; Sheng, Z.H. M11 restricts Parkin-mediated mitophagy in mature neurons by maintaining ER-mitochondrial contacts. Nat. Commun. 2019, 10, 3645. [CrossRef]
125. Kania, E.; Roest, G.; Vervliet, T.; Parys, J.B.; Bultynck, G. IP3 Receptor-Mediated Calcium Signaling and Its Role in Autophagy in Cancer. Front. Oncol. 2017, 7, 140. [CrossRef]
126. Gherardi, G.; Di Marco, G.; Rizzuto, R.; Mammarkar, C. Crosstalk between Mitochondrial Ca2+ Uptake and Autophagy in Skeletal Muscle. Oxidative Med. Cell. Longev. 2019, 2019, 184321. [CrossRef]
127. Mallilankaram, K.; Cadenas, C.; Doonan, P.J.; Chandramoorthy, H.C.; Irrink, K.M.; Golenar, T.; Csordas, G.; Madireddi, P.; Yang, J.; Muller, M.; et al. MCU1 is an essential component of mitochondrial Ca2+ uptake that regulates cellular metabolism. Nat. Cell Biol. 2012, 14, 1356–1363. [CrossRef]
128. Decuypere, J.P.; Parys, J.B.; Bultynck, G. ITPRs/inositol 1,4,5-trisphosphate receptors in autophagy: From enemy to ally. Autophagy 2015, 11, 1944–1948. [CrossRef]
129. Gomez-Suaga, P.; Paullusson, S.; Stoica, R.; Noble, W.; Hanger, D.P.; Miller, C.C.J. The ER-Mitochondria Tethering Complex VAPB-TPP1 is essential for autophagy. Curr. Biol. 2017, 27, 371–385. [CrossRef]
130. Pacher, P.; Thomas, A.P.; Hajnoczky, G. Ca2+ marks: Miniature calcium signals in single mitochondria driven by ryanodine receptors. Proc. Natl. Acad. Sci. USA 2002, 99, 2380–2385. [CrossRef]
131. Collins, T.J.; Lipp, P.; Berridge, M.J.; Bootman, M.D. Mitochondrial Ca2+ uptake depends on the spatial and temporal profile of cytosolic Ca2+ signals. J. Biol. Chem. 2001, 276, 26411–26420. [CrossRef] [PubMed]
132. Cao, J.L.; Adaniya, S.M.; Cypress, M.W.; Suzuki, Y.; Kusakari, Y.; Jhun, B.S.; Jin, O. Role of mitochondrial Ca2+ homeostasis in cardiac muscle. Arch. Biochem. Biophys. 2019, 663, 276–287. [CrossRef] [PubMed]
133. De Stefani, D.; Rizzuto, R.; Pozzan, T. Enjoy the Trip: Calcium in Mitochondria Back and Forth. Annu. Rev. Biochem. 2016, 85, 161–192. [CrossRef] [PubMed]
134. Mammarkar, C.; Raffaello, A.; Vecellio Reane, D.; Rizzuto, R. Molecular structure and pathophysiological roles of the Mitochondrial Calcium Uniporter. Biochim. Biophys. Acta 2016, 1863, 2457–2464. [CrossRef]
135. Shoshan-Barmatz, V.; Krelin, Y.; Shteifer-Kuzmine, A. VDAC1 functions in Ca2+ homeostasis and cell life and death in health and disease. Cell Calcium 2018, 69, 81–100. [PubMed]
136. Deluca, H.F.; Engstrom, G.W. Calcium uptake by rat kidney mitochondria. Proc. Natl. Acad. Sci. USA 1961, 47, 1744–1750. [CrossRef]
137. Vasington, F.D.; Murphy, J.V. Ca ion uptake by rat kidney mitochondria and its dependence on respiration and phosphorylation. J. Biol. Chem. 1962, 237, 2670–2677. [CrossRef]
138. Jiang, D.; Zhao, L.; Clapham, D.E. Genome-wide RNAi screen identifies Letm1 as a mitochondrial Ca2+/H+ antiporter. Science 2009, 326, 144–147. [CrossRef]
139. Perocchi, F.; Gohil, V.M.; Girgis, H.S.; Bao, X.R.; McCombs, J.E.; Palmer, A.E.; Mootha, V.K. MICU1 encodes a mitochondrial EF hand protein required for Ca2+ uptake. Nature 2010, 467, 291–296. [CrossRef]
140. Palty, R.; Silverman, W.F.; Hershfield, M.; Caporale, T.; Senisi, S.L.; Parnis, J.; Norle, C.; Fishman, D.; Sho-shan-Barmatz, V.; Herrmann, S., et al. NCLX is an essential component of mitochondrial Ca2+/Na+ exchange. J. Biol. Chem. 2010, 285, 436–441. [CrossRef]
141. Raffaello, A.; De Stefani, D.; Sabbadin, D.; Teardo, E.; Merli, G.; Picard, A.; Checchetto, V.; Moro, S.; Szabo, I.; Rizzuto, R. The mitochondrial calcium uniporter is a multimer that can include a dominant-negative pore-forming subunit. EMBO J. 2013, 32, 2362–2376. [CrossRef] [PubMed]
142. Plosanich, M.; Bogorad, R.L.; Sancak, Y.; Kamer, K.J.; Strittmatter, L.; Li, A.A.; Girgis, H.S.; Kuchimanchi, S.; De Groot, J.; Speciner, L.; et al. MICU2, a paralog of MICU1, resides within the mitochondrial uniporter complex to regulate calcium handling. PLoS ONE 2013, 8, e55785. [CrossRef] [PubMed]
143. Sancak, Y.; Markhard, A.L.; Kitami, T.; Kovacs-Bogdan, E.; Kamer, K.J.; Udeshi, N.D.; Carr, S.A.; Chaudhuri, D.; Clapham, D.E.; Li, A.A.; et al. EMRE is an essential component of the mitochondrial calcium uniporter complex. Science 2013, 342, 1379–1382. [CrossRef] [PubMed]
144. Hoffman, N.E.; Chandramoorthy, H.C.; Shammugapriya, S.; Zhang, X.Q.; Vallem, S.; Doonan, P.J.; Mallilankaram, K.; Guo, S.; Rajan, S.; Elrod, J.W.; et al. SLC25A23 augments mitochondrial Ca2+ uptake, interacts with MCU, and induces oxidative stress-mediated cell death. Mol. Biol. Cell 2014, 25, 936–947. [CrossRef]
145. Fan, M.; Zhang, J.; Tsai, C.W.; Orlando, B.J.; Rodriguez, M.; Xu, Y.; Liao, M.; Tsai, M.F.; Feng, L. Structure and mechanism of the mitochondrial Ca2+ uniporter holocomplex. Nature 2020, 582, 129–133. [CrossRef]
146. Yoo, J.; Wu, M.; Yin, Y.; Herzik, M.A., Jr.; Lander, G.C.; Lee, S.Y. Cryo-EM structure of a mitochondrial calcium uniporter. Science 2018, 361, 506–511. [CrossRef]
147. Fan, C.; Fan, M.; Orlando, B.J.; Fastman, N.M.; Zhang, J.; Xu, Y.; Chambers, M.G.; Xu, P.; Perry, K.; Liao, M.; et al. X-ray and cryo-EM structures of the mitochondrial calcium uniporter. Nature 2018, 559, 575–579. [CrossRef]
148. Carafofoli, E.; Lehninger, A.L. A survey of the interaction of calcium ions with mitochondria from different tissues and species. Biochem. J. 1971, 122, 681–690. [CrossRef]
149. Rottenberg, H.; Scarpa, A. Calcium uptake and membrane potential in mitochondria. Biochemistry 1974, 13, 4811–4817. [CrossRef]
150. Xie, A.; Zhou, A.; Liu, H.; Shi, G.; Liu, M.; Boheler, K.R.; Dudley, S.C., Jr. Mitochondrial Ca2+ flux modulates spontaneous electrical activity in ventricular cardiomyocytes. PLoS ONE 2018, 13, e0200448. [CrossRef]
Zhao, Z.; Gordan, R.; Wen, H.; Fefelova, N.; Zang, W.J.; Xie, L.H. Modulation of intracellular calcium waves and triggered activities by mitochondrial ca flux in mouse cardiomyocytes. PLoS ONE 2013, 8, e80574. [CrossRef] [PubMed]

Haumann, J.; Camara, A.K.S.; Gadicherla, A.K.; Navarro, C.D.; Boelens, A.D.; Blomeyer, C.A.; Dash, R.K.; Boswell, M.R.; Kwok, W.M.; Stowe, D.F. Slow Ca\(^{2+}\) Efflux by Ca\(^{2+}\)/H\(^{+}\) Exchange in Cardiac Mitochondria Is Modulated by Ca\(^{2+}\) Re-uptake via MCU, Extra-Mitochondrial pH, and H\(^{+}\) Pumping by FOF1-ATPase. Front. Physiol. 2018, 9, 1914. [CrossRef] [PubMed]

Carvalho, E.J.; Stathopoulos, P.B.; Madesh, M. Regulation of Ca\(^{2+}\) exchanges and signaling in mitochondria. Curr. Opin. Physiol. 2020, 17, 197–206. [CrossRef] [PubMed]

Bick, A.G.; Calvo, S.E.; Mootha, V.K. Evolutionary diversity of the mitochondrial calcium uniporter. Science 2012, 336, 886. [CrossRef] [PubMed]

Kamer, K.J.; Mootha, V.K. The molecular era of the mitochondrial calcium uniporter. Nat. Rev. Mol. Cell Biol. 2015, 16, 545–553. [CrossRef]

Drago, I.; De Stefani, D.; Rizzuto, R.; Pozzan, T. Mitochondrial Ca\(^{2+}\) uptake contributes to buffering cytoplasmic Ca\(^{2+}\) peaks in cardiomyocytes. Proc. Natl. Acad. Sci. USA 2012, 109, 12986–12991. [CrossRef]

Kwong, J.Q.; Lu, X.; Correll, R.N.; Schwanekamp, J.A.; Vagnozzi, R.J.; Sargent, M.A.; York, A.J.; Zhang, J.; Bers, D.M.; Molkentin, J.D. The Mitochondrial Calcium Uniporter Selectively Matches Metabolic Output to Acute Contractile Stress in the Heart. Cell Rep. 2015, 12, 15–22. [CrossRef]

Luongo, T.S.; Lambert, J.P.; Yuan, A.; Zhang, X.; Gross, P.; Song, J.; Shamugapriya, S.; Gao, E.; Jain, M.; Houser, S.R.; et al. The Adrenergic Signaling Regulates the Mitochondrial Calcium Uniporter Matchess Energetic Supply with Cardiac Workload during Stress and Modulates Permeability Transition. Cell Rep. 2015, 12, 23–34. [CrossRef]

Uchi, J.; Jhun, B.S.; Xu, S.; Hurst, S.; Rafaello, A.; Liu, X.; Yi, B.; Zhang, H.; Gross, P.; Mishra, J.; et al. Adrenergic signaling regulates mitochondrial Ca\(^{2+}\) uptake through Pyk2-dependent tyrosine phosphorylation of the mitochondrial Ca\(^{2+}\) uniporter. Antioxid. Redox Signal. 2014, 21, 863–879. [PubMed]

Lambert, J.P.; Luongo, T.S.; Tomar, D.; Jadiya, P.; Gao, E.; Zhang, X.; Lucchese, A.M.; Kolmetzky, D.W.; Shah, N.S.; Elrod, J.W. MCUB Regulates the Molecular Composition of the Mitochondrial Calcium Uniporter Channel to Limit Mitochondrial Calcium Overload During Stress. Circulation 2019, 140, 1720–1733. [CrossRef]

Patron, M.; Checcheto, V.; Rafaello, A.; Teardo, E.; Vecellio Reane, D.; Mantoan, M.; Granatiero, V.; Szabo, I.; De Stefani, D.; Rizzuto, R. MICU1 and MICU2 finely tune the mitochondrial Ca\(^{2+}\) uniporter by exerting opposing effects on MCU activity. Mol. Cell 2014, 53, 726–737. [CrossRef] [PubMed]

Hoffman, N.E.; Chandramoorthy, H.C.; Shamugapriya, S.; Zhang, X.; Rajan, S.; Mallilankaraman, K.; Gandhirajan, R.K.; Vagnozzi, R.J.; Ferrer, L.M.; Sreekrishnanilayam, K.; et al. MICU1 motifs define mitochondrial calcium uniporter binding and activity. Cell Rep. 2013, 5, 1576–1588. [CrossRef] [PubMed]

Alam, M.R.; Groschner, L.N.; Parichatikanond, W.; Kuo, L.; Bondarenko, A.I.; Rost, R.; Waldeck-Weiermair, M.; Malli, R.; Graier, W.F. Mitochondrial Ca\(^{2+}\) uptake 1 (MICU1) and mitochondrial Ca\(^{2+}\) uniporter (MCU) contribute to metabolism-secretion coupling in clonal pancreatic beta-cells. J. Biol. Chem. 2012, 287, 34445–34454. [CrossRef]

Bick, A.G.; Wakimoto, H.; Kamer, K.J.; Sancak, Y.; Geldberger, O.; Axelsson, A.; DeLaughter, D.M.; Gorham, J.M.; Mootha, V.K.; Seidman, J.G.; et al. Cardiovascular homeostasis dependence on MICU2, a regulatory subunit of the mitochondrial calcium uniporter. Proc. Natl. Acad. Sci. USA 2017, 114, E9966–E9104. [PubMed]

Waldeck-Weiermair, M.; Malli, R.; Parichatikanond, W.; Gottschalk, B.; Madreiter-Sokolowski, C.T.; Klec, C.; Rost, R.; Graier, W.F. Rearrangement of MICU1 multimers for activation of MCU is solely controlled by cytosolic Ca\(^{2+}\). Sci. Rep. 2015, 5, 15602. [CrossRef]

Vais, H.; Mallilankaraman, K.; Mak, D.D.; Hoff, H.; Payne, R.; Tanis, J.E.; Foskett, J.K. EMRE Is a Matrix Ca\(^{2+}\) Sensor that Governs Gatekeeping of the Mitochondrial Ca\(^{2+}\) Uniporter. Cell Rep. 2016, 14, 403–410. [CrossRef]

Dong, T.; Dong, Z.; Shanmugapriya, S.; Koch, D.A.; Thomas, T.; Hoffman, N.E.; Timbalia, S.A.; Goldman, S.J.; Breves, S.L.; Corbally, D.P.; et al. MCUR1 Is a Scaffold Factor for the MCU Complex Function and Promotes Mitochondrial Bioenergetics. Cell Rep. 2016, 15, 1673–1685. [CrossRef]

Nemani, N.; Shanmugapriya, S.; Madesh, M. Molecular regulation of MCU: Implications in physiology and disease. Cell Calcium 2018, 74, 86–93. [CrossRef]

Chaudhuri, D.; Artiga, D.J.; Abiria, S.A.; Clapham, D.E. Mitochondrial calcium uniporter regulator 1 (MCUR1) regulates the calcium threshold for the mitochondrial permeability transition. Proc. Natl. Acad. Sci. USA 2016, 113, E1872–E1880. [CrossRef]

Dong, Z.; Shanmugapriya, S.; Tomar, D.; Siddiqui, N.; Lynch, S.; Nemani, N.; Breves, S.L.; Zhang, X.; Tripathi, A.; Palaniappan, P.; et al. Mitochondrial Ca\(^{2+}\) Uniporter Is a Mitochondrial Luminal Redox Sensor that Augments MCU Channel Activity. Mol. Cell 2017, 65, 1014–1028.e7. [CrossRef]

Jhun, B.S.; Mishra, J.; Monaco, S.; Fu, D.; Jiang, W.; Sheu, S.S.; O-Uchi, J. The Mitochondrial Ca\(^{2+}\) uniporter: Regulation by auxiliary subunits and signal transduction pathways. Am. J. Physiol. Cell Physiol. 2016, 311, C67–C80. [CrossRef] [PubMed]

Beutner, G.; Sharma, V.K.; Lin, L.; Ryu, S.Y.; Dirksen, R.T.; Sheu, S.S. Type 1 ryanodine receptor in cardiac mitochondria: Transducer of excitation-metabolism coupling. Biochim. Biophys. Acta 2005, 1717, 1–10. [CrossRef] [PubMed]

Jin, O.; Jhun, B.S.; Hurst, S.; Bisetto, S.; Gross, P.; Chen, M.; Kettlewell, S.; Park, J.; Oyamada, H.; Smith, G.L.; et al. Overexpression of ryanodine receptor type 1 enhances mitochondrial fragmentation and Ca\(^{2+}\)-induced ATP production in cardiac H9c2 myoblasts. Am. J. Physiol. Heart Circ. Physiol. 2013, 305, H1736–H1751.
174. Buntinas, L.; Gunter, K.K.; Sparagna, G.C.; Gunter, T.E. The rapid mode of calcium uptake into heart mitochondria (RaM): Comparison to RaM in liver mitochondria. *Biochim. Biophys. Acta* 2001, 1504, 248–261. [CrossRef]

175. Gunter, T.E.; Gunter, K.K.; Sheu, S.S.; Gavin, C.E. Mitochondrial calcium transport: Physiological and pathological relevance. *Am. J. Physiol.* 1994, 267 Pt 1, C315–C339. [CrossRef] [PubMed]

176. Motloch, L.J.; Labrig, R.; Gebing, T.; Reda, S.; Schwaiger, A.; Leitner, J.; Wolny, M.; Eckardt, L.; Hoppe, U.C. By Regulating Mitochondrial Ca\(^{2+}\)-Uptake UCP2 Modulates Intracellular Ca\(^{2+}\). *PLoS ONE* 2016, 11, e0148359. [CrossRef] [PubMed]

177. Michels, G.; Khan, I.F.; Endres-Becker, J.; Rottlaender, D.; Herzig, S.; Ruhrparwar, A.; Wahlers, T.; Hoppe, U.C. Regulation of the human cardiac mitochondrial Ca\(^{2+}\) uptake by 2 different voltage-gated Ca\(^{2+}\) channels. *Circulation* 2009, 119, 2435–2443. [CrossRef] [PubMed]

178. Motloch, L.J.; Gebing, T.; Reda, S.; Schwaiger, A.; Wolny, M.; Hoppe, U.C. UCP3 Regulates Single-Channel Activity of the Cardiac mCa1. *J. Membr. Biol.* 2016, 249, 577–584. [CrossRef]

179. Bogeski, I.; Gulaboski, R.; Kappl, R.; Mirceski, V.; Stefova, M.; Petreska, J.; Hoth, M. Calcium binding and transport by coenzyme Q. *J. Am. Chem. Soc.* 2011, 133, 9293–9303. [CrossRef]

180. Waldeck-Weiermair, M.; Jean-Quartier, C.; Rost, R.; Khan, M.J.; Malli, R.; Graier, W.F. Leucine zipper EF hand-containing transmembrane protein 1 (Letm1) and uncoupling proteins 2 and 3 (UCP2/3) contribute to two distinct mitochondrial Ca\(^{2+}\) uptake pathways. *J. Biol. Chem.* 2011, 286, 28444–28455. [CrossRef]

181. Ricquier, D.; Bouillaud, F. The uncoupling protein homologues: UCP1, UCP2, UCP3, StUCP and AtUCP. *Biochem. J.* 1990, 267 Pt 1, 357–3581.e4. [CrossRef] [PubMed]

182. Trenker, M.; Malli, R.; Fertschai, I.; Levak-Frank, S.; Graier, W.F. Uncoupling proteins 2 and 3 are fundamental for mitochondrial membrane (MAM). *Biochim. Biophys. Acta* 2013, 1831–1833, 2542–2559. [CrossRef]

183. Waldeck-Weiermair, M.; Malli, R.; Naghdi, S.; Trenker, M.; Kahn, M.J.; Graier, W.F. The contribution of UCP2 and UCP3 to single-channel properties of a MCU-dependent Ca\(^{2+}\) inward current in mitochondria. *Pflug. Arch. Eur. J. Physiol.* 2015, 467, 2509–2518. [CrossRef]

184. De Marchi, U.; Castelbou, C.; Demaurex, N. Uncoupling protein 3 (UCP3) modulates the activity of Sarco/endoplasmic reticulum Ca\(^{2+}\)-ATPase (SERCA) by decreasing mitochondrial ATP production. *J. Biol. Chem.* 2011, 286, 32533–32541. [CrossRef]

185. Mehta, S.L.; Li, P.A. Neuroprotective role of mitochondrial uncoupling protein 2 in cerebral stroke. *Biochim. Biophys. Acta* 2011, 1812, 248–261. [CrossRef]

186. Bogeski, I.; Gulaboski, R.; Kappl, R.; Mirceski, V.; Stefova, M.; Petreska, J.; Hoth, M. Calcium binding and transport by coenzyme Q. *J. Am. Chem. Soc.* 2011, 133, 9293–9303. [CrossRef]

187. Motloch, L.J.; Larbig, R.; Gebing, T.; Reda, S.; Schwaiger, A.; Leitner, J.; Wolny, M.; Eckardt, L.; Hoppe, U.C. By Regulating Mitochondrial Ca\(^{2+}\)-Uptake UCP2 Modulates Intracellular Ca\(^{2+}\). *PLoS ONE* 2016, 11, e0148359. [CrossRef] [PubMed]

188. Michel, G.; Khan, I.F.; Endres-Becker, J.; Rottlaender, D.; Herzig, S.; Ruhrparwar, A.; Walehrs, T.; Hoppe, U.C. Regulation of the human cardiac mitochondrial Ca\(^{2+}\) uptake by 2 different voltage-gated Ca\(^{2+}\) channels. *Circulation* 2009, 119, 2435–2443. [CrossRef] [PubMed]

189. D'Eletto, M.; Rossin, F.; Occhigrossi, L.; Farrace, M.G.; Faccenda, D.; Desai, R.; Marchi, S.; Refolo, G.; Falasca, L.; Antonioli, M.; et al. Transglutaminase Type 2 Regulates ER-Mitochondria Contact Sites by Interacting with GRP75. *Cell Rep.* 2018, 25, 3573–3581.e4. [CrossRef]

190. Szabadkai, G.; Bianchi, K.; Varnai, P.; De Stefani, D.; Wieckowski, M.R.; Cavagna, D.; Nagy, A.; Balla, T.; Rizzuto, R. Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca\(^{2+}\) channels. *J. Cell Biol.* 2006, 175, 901–911. [CrossRef]
201. Xu, H.; Guan, N.; Ren, Y.L.; Wei, Q.J.; Tao, Y.H.; Yang, G.S.; Liu, X.Y.; Bu, D.F.; Zhang, Y.; Zhu, S.N. IP3R-Grp75-VDAC1-MCU calcium regulation axis antagonists protect podocytes from apoptosis and decrease proteinuria in an Adriamycin nephropathy rat model. BMC Nephrol. 2018, 19, 140. [CrossRef] [PubMed]

202. Liu, Y.; Ma, X.; Fujio, H.; Liu, J.; Chen, S.; Zhu, X. DJ-1 regulates the integrity and function of ER-mitochondria association through interaction with IP3R3-Grp75-VDAC1. Proc. Natl. Acad. Sci. USA 2019, 116, 25322–25328. [CrossRef] [PubMed]

203. Paillard, M.; Tubbs, E.; Thiebaut, P.A.; Gomez, L.; Fauconnier, J.; Da Silva, C.C.; Teixeira, G.; Mewton, N.; Belaidi, E.; Durand, A.; et al. Depressing mitophagy-ER-endoplasmic reticulum interactions protects cardiomyocytes from lethal hypoxia-reoxygenation injury. Circulation 2013, 128, 1555–1565. [CrossRef] [PubMed]

204. Simmen, T.; Aslan, J.E.; Blagoveshchenskaya, A.D.; Thomas, L.; Wan, L.; Xiang, Y.; Feliciangeli, S.F.; Hung, C.H.; Crump, C.M.; Thomas, G. PACS-2 controls endoplasmic reticulum-mitochondria communication and Bid-mediated apoptosis. EMBO J. 2005, 24, 717–729. [CrossRef]

205. Myhill, N.; Lynes, E.M.; Nanji, J.A.; Blagoveshchenskaya, A.D.; Fei, H.; Thomas, G.; Simmen, T. PACS-2 controls endoplasmic reticulum-mitochondria communication and Bid-mediated apoptosis. EMBO J. 2005, 24, 717–729. [CrossRef]

206. Wu, Z.; Bowen, W.D. Role of sigma-1 receptor C-terminal segment in inositol 1,4,5-trisphosphate receptor activation: Constitutive enhancement of calcium signaling in MCF-7 tumor cells. J. Biol. Chem. 2008, 283, 28198–28215. [CrossRef]

207. Su, T.P.; Su, T.C.; Nakamura, Y.; Tsai, S.Y. The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems. Trends Pharm. Sci. 2016, 37, 262–278. [CrossRef]

208. Matsuzaki, H.; Fujimoto, T.; Tanaka, M.; Shirasawa, S. Tesp1 is a novel component of mitochondria-associated endoplasmic reticulum membranes and affects mitochondrial calcium flux. Biochim. Biophys. Res. Commun. 2013, 433, 322–326. [CrossRef]

209. Wu, L.; Zhang, D.; Zhou, L.; Pei, Y.; Zhuang, Y.; Cui, W.; Chen, J. FUN14 domain-containing 1 promotes breast cancer proliferation and migration by activating calcium-NFATC1-BMI1 axis. EBioMedicine 2019, 41, 384–394. [CrossRef]

210. Ren, J.; Sun, M.; Zhou, H.; Ajoobabady, A.; Zhou, Y.; Tao, J.; Sowers, J.R.; Zhang, Y. FUNDC1 interacts with FBXL2 to govern mitochondrial integrity and cardiac function through an IP3R3-dependent manner in obesity. Sci. Adv. 2020, 6, eabc8561. [CrossRef]

211. Wu, W.; Lin, C.; Wu, K.; Jiang, L.; Wang, X.; Li, W.; Zhuang, H.; Zhang, X.; Chen, H.; Li, S.; et al. FUNDC1 regulates mitochondrial dynamics at the ER-mitochondrial contact site under hypoxic conditions. EMBO J. 2015, 136, 1386–1388. [CrossRef] [PubMed]

212. De Strooper, B. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007, 8, 141–146. [CrossRef] [PubMed]

213. Filadi, R.; Greotti, E.; Turacchio, G.; Luini, A.; Pozzan, T.; Pizzo, P. Presenilin 2 Modulates Endoplasmic Reticulum-Mitochondria Coupling by Tuning the Antagonistic Effect of MitoFusin-2. Cell Rep. 2016, 15, 2226–2238. [CrossRef] [PubMed]

214. Zampese, E.; Gasolato, C.; Kipanu, M.J.; Bortolozzi, M.; Pozzan, T.; Pizzo, P. Presenilin 2 modulates endoplasmic reticulum (ER)-mitochondria interactions and Ca2+ cross-talk. Proc. Natl. Acad. Sci. USA 2011, 108, 2777–2782. [CrossRef] [PubMed]

215. Drago, I.; Pizzo, P.; Pozzan, T. After half a century mitochondrial Ca2+ homeostasis and viability. J. Am. Coll. Cardiol. 2004, 43, 93–97. [CrossRef]

216. Drago, I.; Pizzo, P.; Pozzan, T. Microdomains of intracellular Ca2+: Molecular determinants and functional consequences. Physiol. Rev. 2006, 86, 369–408. [CrossRef]

217. Tsai, M.F.; Jiang, D.; Zhao, L.; Clapham, D.; Miller, C. Functional reconstitution of the mitochondrial Ca2+/H+ antipporter Letm1. J. Gen. Physiol. 2014, 143, 67–73. [CrossRef]

218. Palty, R.; Ohana, E.; Hershshinkel, M.; Volokita, M.; Elgazar, V.; Beharier, O.; Silverman, W.F.; Argaman, M.; Sekler, I. Lithium-calciumpexchanger is essential for Ca2+ homeostasis and viability. Nature 2017, 545, 93–97. [CrossRef]

219. Morciano, G.; Honora, M.; Campo, G.; Aquila, G.; Rizzo, P.; Giorgi, C.; Wieckowski, M.R.; Pinton, P. Mechanistic Role of mPTP in Ischemia-Reperfusion Injury. Adv. Exp. Med. Biol. 2014, 802, 169–189. [CrossRef]

220. De Marchi, E.; Honora, M.; Giorgi, C.; Pinton, P. The mitochondrial permeability transition pore is a dispensable element for mitochondrial calcium efflux. Cell Calcium 2014, 56, 1–13. [CrossRef] [PubMed]

221. Saotome, M.; Katoh, H.; Satoh, H.; Nagasaka, S.; Yoshihara, S.; Terada, H.; Hayashi, H. Mitochondrial membrane potential modulates regulation of mitochondrial Ca2+ in rat ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 2005, 288, H1820–H1828. [CrossRef] [PubMed]

222. Gong, G.; Liu, X.; Wang, W. Regulation of metabolism in individual mitochondria during excitation-contraction coupling. J. Mol. Cell. Cardiol. 2014, 76, 235–246. [CrossRef]

223. Akopova, O.V. The role of mitochondrial permeability transition pore in transmembrane Ca2+-exchange in mitochondria. Ukrains’ kyi Biokhimichnyi Zhurnal (1999) 2008, 80, 40–47. [CrossRef] [PubMed]

224. Bhosale, G.; Sharpe, J.A.; Sundier, S.Y.; Duchen, M.R. Calcium signaling as a mediator of cell energy demand and a trigger to cell death. Ann. N. Y. Acad. Sci. 2015, 1350, 107–116. [CrossRef] [PubMed]

225. Gustafsson, A.B.; Gottlieb, R.A. Heart mitochondria: Gates of life and death. Cardiovasc. Res. 2008, 77, 334–343. [CrossRef] [PubMed]
278. Ikeda, G.; Matoba, T.; Nakano, Y.; Nagaoka, K.; Ishikita, A.; Nakano, K.; Funamoto, D.; Sunagawa, K.; Egashira, K. Nanoparticle-Mediated Targeting of Cyclosporine A Enhances Cardioprotection Against Ischemia-Reperfusion Injury Through Inhibition of Mitochondrial Permeability Transition Pore Opening. Sci. Rep. 2016, 6, 20467. [CrossRef]

279. Jahandiez, V.; Cour, M.; Bochaton, T.; Abrial, M.; Loufouat, J.; Gharib, A.; Varennes, A.; Ovize, M.; Argaud, L. Fast therapeutic hypothermia prevents post-cardiac arrest syndrome through cyclophilin D-mediated mitochondrial permeability transition inhibition. Basic Res. Cardiol. 2017, 112, 35. [CrossRef]

280. Monaco, G.; Decrock, E.; Akl, H.; Ponsaerts, R.; Vervliet, T.; Luyten, T.; De Maeyer, M.; Missiaen, L.; Distelhorst, C.W.; De Smedt, H.; et al. Selective regulation of IP3-receptor-mediated Ca\(^{2+}\) signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-XL. Cell Death Differ. 2012, 19, 295–309. [CrossRef]

281. El-Hayek, R.; Antoniu, B.; Wang, J.; Hamilton, S.L.; Ikemoto, N. Identification of calcium release-triggering and blocking regions of the II-III loop of the skeletal muscle dihydropyridine receptor. J. Biol. Chem. 1995, 270, 22116–22118. [CrossRef]

282. Dulhunty, A.F.; Cengia, L.; Young, J.; Harvey, P.J.; Lamb, G.D.; Chan, Y.N.; Wimmer, N.; Toth, I.; Casarotto, M.G. Functional implications of modifying RyR-activating peptides for membrane permeability. Br. J. Pharmacol. 2005, 144, 743–754. [CrossRef] [PubMed]

283. Xiao, L.; Gurrola, G.B.; Zhang, J.; Valdivia, C.R.; San Martin, M.; Zamudio, F.Z.; Zhang, L.; Possani, L.D.; Valdivia, H.H. Structure-function relationships of peptides forming the calcin family of ryanodine receptor ligands. J. Gen. Physiol. 2016, 147, 375–394. [CrossRef] [PubMed]

284. Naia, L.; Ferreira, I.L.; Ferreiro, E.; Rego, A.C. Mitochondrial Ca\(^{2+}\) handling in Huntington’s disease—Role of the II-III loop of the skeletal muscle dihydropyridine receptor. J. Biol. Chem. 2012, 287, 1995–2004. [CrossRef] [PubMed]

285. Zhou, H.; Wang, S.; Hu, S.; Chen, Y.; Ren, J. ER-Mitochondria Microdomains in Cardiac Ischemia-Reperfusion Injury: A Fresh Perspective. Front. Physiol. 2018, 9, 755. [CrossRef]

286. Hansson, M.J.; Mattiasson, G.; Månsson, R.; Karlsson, J.; Keep, M.F.; Waldmeier, P.; Ruegg, U.T.; Dumont, J.M.; Besseghir, K.; Kerkhofs, M.; Bultynck, G.; Vervliet, T.; Monaco, G. Therapeutic implications of novel peptides targeting ER-mitochondria transition in brain-derived mitochondria. J. Bioenerg. Biomembr. 2021, 839. [CrossRef]

287. Elan, G.; Matoba, T.; Nakano, Y.; Nagaoka, K.; Ishikita, A.; Nakano, K.; Funamoto, D.; Sunagawa, K.; Egashira, K. Nanoparticle-Mediated Targeting of Cyclosporine A Enhances Cardioprotection Against Ischemia-Reperfusion Injury Through Inhibition of Mitochondrial Permeability Transition Pore Opening. Sci. Rep. 2016, 6, 20467. [CrossRef]

288. Naia, L.; Ferreira, I.L.; Ferreiro, E.; Rego, A.C. Mitochondrial Ca\(^{2+}\) handling in Huntington’s disease—Role of the II-III loop of the skeletal muscle dihydropyridine receptor. J. Biol. Chem. 2012, 287, 1995–2004. [CrossRef] [PubMed]

289. Orange, G.; Pahima, H.; Ben-Hail, D.; Shoshan-Barmatz, V. The role of calcium in VDAC1 oligomerization and mitochondria-mediated apoptosis. Biochim. Biophys. Acta 2013, 1833, 1745–1754. [CrossRef]

290. Monaco, G.; Decrock, E.; Akl, H.; Ponsaerts, R.; Vervliet, T.; Luyten, T.; De Maeyer, M.; Missiaen, L.; Distelhorst, C.W.; De Smedt, H.; et al. Selective regulation of IP3-receptor-mediated Ca\(^{2+}\) signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-XL. Cell Death Differ. 2012, 19, 295–309. [CrossRef]

291. Kerkhofs, M.; Bultynck, G.; Vervliet, T.; Monaco, G. Therapeutic implications of novel peptides targeting ER-mitochondria transition in brain-derived mitochondria. J. Bioenerg. Biomembr. 2021, 839. [CrossRef] [PubMed]

292. Hansson, M.J.; Mattiasson, G.; Månsson, R.; Karlsson, J.; Keep, M.F.; Waldmeier, P.; Ruegg, U.T.; Dumont, J.M.; Besseghir, K.; Kerkhofs, M.; Bultynck, G.; Vervliet, T.; Monaco, G. Therapeutic implications of novel peptides targeting ER-mitochondria transition in brain-derived mitochondria. J. Bioenerg. Biomembr. 2021, 839. [CrossRef] [PubMed]

293. Hansson, M.J.; Mattiasson, G.; Månsson, R.; Karlsson, J.; Keep, M.F.; Waldmeier, P.; Ruegg, U.T.; Dumont, J.M.; Besseghir, K.; Elmér, E. The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria. J. Bioenerg. Biomembr. 2004, 36, 407–413. [CrossRef] [PubMed]

294. Belosludtseva, N.V.; Starinets, V.S.; Mikheeva, I.B.; Serov, D.A.; Astashev, M.E.; Belosludtsev, K.N. Effect of the MPT Pore Inhibitor Alisporivir on the Development of Mitochondrial Dysfunction in the Heart Tissue of Diabetic Mice. Biochem. Pharmacother. 2016, 10, 839. [CrossRef]

295. Guo, R.; Si, R.; Scott, B.T.; Makino, A. Mitochondrial connexin40 regulates mitochondrial calcium uptake in coronary endothelial cells. Am. J. Physiol. Cell Physiol. 2017, 312, C398–C406. [CrossRef]

296. Srisakuldee, W.; Makazan, Z.; Nickel, B.E.; Zhang, F.; Thiliveris, J.A.; Pasumarthi, K.B.; Kardami, E. The FGF-2-triggered protection of cardiac subsarcolemmal mitochondria from calcium overload is mitochondrial connexin 43-dependent. Cardiovasc. Res. 2014, 103, 72–80. [CrossRef]